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1. Summary
The prospect of the work presented in this thesis has been to engineer Cre recombinase to
recognize and recombine a sequence from an HIV-1 Long Terminal Repeat (LTR),
characterize the recombination proficiency of the evolved recombinase in mammalian
cells and explore the potential of the recombinase for a novel antiretroviral strategy.
Retroviruses like HIV-1 integrate into the host chromosome and persist as a provirus
flanked by LTRs. Establishment of the provirus is an obligatory step in the retroviral life-
cycle and serves to maintain viral sequences in the infected cell. The LTRs of proviral
DNA direct the expression of viral genes.
A modified Cre recombinase recognising sequences within each LTR of proviral DNA
could mediate excision of the viral coding sequences eliminating the intact provirus and
represents a novel direct antiviral strategy targeting the provirus. To realize the potential
of a genetic surgery targeting an integrated provirus, it is essential to determine whether
such a recombinase can actually be generated that can recombine a sequence within a
retroviral LTR. The laboratory evolved Cre recombinase variants with altered site-
specificity have proved that it is possible to generate tailored recombinases and hold
promise for increasing the applicability of these recombinases for therapeutic purposes.
An in vitro evolution strategy called substrate-linked protein evolution strategy (SliDE)
was used to evolve a novel Cre recombinase variant recombining an asymmetric
sequence termed loxltr belonging to an HIV-1 LTR in E.coli.
To obtain the novel Cre variant, an extensive evolution approach was taken, traversing
through six pallindromic loxltr subsets, to achieve specificity for the asymmetric loxltr. A
novel feature of this strategy was the use of a combinatorial SLiDE by splitting the final
loxltr target site into six sub-sets to achieve recombination at the loxltr target. It was
possible to generate functional recombinases that recognize the asymmetric loxltr by
combining recombinases which separately recognize the loxltr subsets with different
mutations all present in the final substrate using DNA shuffling. The synergistic effect of
the shuffled libraries of the lower subsets led to the generation of recombinases which
recombined the higher loxltr sub-sets and also the final target loxltr. A total of 126
evolution cycles were performed through all the subsets to achieve recombination at the
final target loxltr.
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Sequence analysis of the evolved recombinase variants showed the sequestering of
specific mutations responsible for conferring the change in substrate specificity through
the course of evolution. These mutations were modeled onto the wild type Cre crystal
structure to get an understanding of the interactions that the mutated amino acids might
have with the loxltr target.
To investigate whether the evolved Cre variant, termed Tre, recombines its target in
mammalian cells, a lacZ based reporter assay was developed in Hela cells. The
recombinase mediated recombination in both transient and stable assays.
To improve the activity of Tre in mammalian cells, the codon usage of the recombinase
was adapted to human codon usage preferences by introducing silent base mutations. The
codon-optimised recombinase, hTre was tested in Hela cells using the lacZ based reporter
assay. In comparison to the unoptimised version, hTre displayed improved recombination
potential at the loxltr target both in transient assays and also with the target stably
integrated in the genome.
To explore whether recombinases like hTre can actually be applied for an antiretroviral
therapy targeting an integrated provirus Tat transactivation assays were performed in an
HXB3-LTR based luciferase and chloramphenicol acetyl transferase reporter vectors with
the loxltr cloned within the LTRs to investigate whether hTRE can recombine the loxltr
site in the context of a real HIV-1 LTR.
Transfection of hTre expression vector in presence of Tat resulted in repression of Tat
mediated transactivation of the reporter activity as a result of recombination at the loxltr
sites and three-fold reduction of reporter activity was obtained both for the luciferase and
CAT vectors.
To analyse the extent of recombination mediated by hTre at the loxltr target integrated in
the genome, a PCR based assay was used in Hela cells with the CAT construct stably
integrated into the genome. The evolved recombinase mediated recombination to the
extent of around 10% as detected by the PCR based assay in the CAT stable cell line. In
conclusion this work demonstrates and provides proof of concept that directed evolution
can be utilized to develop tailored molecular scissors for therapeutic DNA surgery.
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2. Introduction
2.1. Site-specific recombination.
Genetic recombination provides a mechanism for generating genetic diversity beyond
that achieved by the independent segregation of chromosomes. Genetic exchange by
recombination occurs not only in animals and plants but also in prokaryotes, viruses,
plasmids, and even in the DNA of cell organelles such as mitochondria.
Homologous recombination occurs between two homologous DNA segments, and there
is relatively little specificity as to the site at which the actual crossover occurs.
Transposition, by contrast, is a process that leaves breaks in DNA that require repair.
Transposases cleave endonucleolytically at each transposon end. The 3’OH ends act as
the nucleophiles for the target cleavage/joining reaction, the 5’ ends of donor DNA
flanking the transposon remain free, until degraded or acted upon by cellular repair
enzymes. The transposable elements are capable of insertion at several different
chromosomal locations and have relatively undefined target site.
Site-specific recombination is distinct from homologous recombination and transposition.
Distinguishing features of conservative site-specific recombination (CSSR) are that
recombination occurs at specific sites within a short region of sequence identity shared by
the participating DNA segments, strand exchange occurs by precise breakage and joining
events and recombination is reciprocal.
2.2.  The λ- integrase family of recombinases.
Site-specific recombination was first discovered through studies of the formation of
lysogens by bacteriophage λ. During the establishment of lysogeny a circular form of
bacteriophage λ  integrates into the bacterial chromosome by intermolecular
recombination between a specific site in the phage attP and a specific site attB on the
bacterial chromosome. Integration requires the phage integrase protein and E.coli
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encoded protein Integration Host Factor (IHF). Integrase also catalyzes the reverse
reaction, excision of the circular λ phage DNA from a bacterial chromosome.
Based on sequence similarity, recombinases from bacteria and yeast have been classified
into the intergrase family, named after the prototypical phage λ, and resolvase-invertase
family, named after the cointegrate-resolving protein encoded by the transposons γδ and
Tn3. These two families are not related in protein sequence and employ different
mechanisms of recombination. The resolvase family includes most transposon-encoded
resolvases and DNA invertases such as Hin and Gin. The λ-integrase family is also
referred to as “ tyrosine recombinases” (Sherratt and Wigley 1998) which include over
100 members identified on the basis of sequence similarity. The most well studied
examples include the integrase protein from bacteriophage λ (Landy 1989), the bacterial
XerC and XerD recombinases (Colloms et al. 1990; McCulloch et al. 1994; Colloms et al.
1996), the Cre recombinase from bacteriophageP1 (Abremski and Hoess 1984) and the
Flp recombinase from Saccharomyces cerevisiae (Sadowski PD, 1995). Site-specific
recombinases (SSR) from the lambda integrase family of enzymes catalyze DNA
rearrangements that are critical for a variety of important biological functions including
the resolution of multimeric plasmids and chromosomes to monomers in order to ensure
faithful segregation upon cell division, antigenic phase variation, dissemination of
antibiotic- and antiseptic- resistance genes, the amplification of yeast 2µ circle copy
number, and the regulation of gene expression (Nunes-Duby, Matsumoto, and Landy
1987; Landy 1993; Esposito and Scocca 1997; Van Duyne 2001).
The defining feature of the λ integrase family is a highly conserved tyrosine nucleophile
in combination with a triad of basic amino acids, the arginine-histidine-arginine triad.
These residues are absolutely essential for full recombination activity.
 λ integrase and its relatives make sequential and ordered pairs of single strand exchanges
between two recombinational partners; the first pair of exchanges form a four way
Holliday junction and the second pair resolve the junction to complete the recombination.
The conserved Tyrosine residue in the recombinase acts as the nucleophile that forms 3’-
phosphotyrosine linkages to DNA releasing free 5’ hydroxyl groups which then attacks
the 3’ phosphotyrosine linkages of the partner strands to form a Holliday junction
intermediate (Argos et al. 1986; Pargellis et al. 1988; Abremski and Hoess 1992; Kwon et
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al. 1997). The mechanistic understanding of the λ integrase family members has greatly
improved with the three dimensional structures of varying complexity published for five
tyrosine recombinases: Cre (Guo, Gopaul, and van Duyne 1997; Gopaul, Guo, and Van
Duyne 1998; Woods et al. 2001; Martin et al. 2002), XerD (Subramanya et al. 1997), HPI
integrase (Hickmann et al., 1997), Flp (Chen et al. 2000) and λ-integrase (Wojciak et al.
2002). These structures have revealed a conserved catalytic domain fold.
The Cre recombinase from bacteriophage P1 is one of the best characterized Int family
member and have been successfully used for various elegant genome manipulation
strategies.
2.3. The Cre-loxP system
The Cre recombinase is a 38 kDa protein encoded by the bacteriophage P1. Its role in P1
life cycle are believed to include resolution of dimeric chromosomes formed following
DNA replication into monomeric P1 DNAs and also the cyclisation of the linear genome
(Sternberg et al. 1986). The DNA sequences where Cre recombinase binding and strand
exchange take place are named loxP (locus of crossover in P1) (Hoess, Ziese, and
Sternberg 1982). The loxP site is a 34 bp sequence composed of two pallindromic
recombinase binding elements (RBE) or core binding elements surrounding a central 8 bp
strand exchange or crossover region (Fig.1).
        Fig.1.  Structure of the loxP recognition sequence. The black arrowheads indicate the strand
cleavage positions within the spacer.
Two recombinase molecules bind to each core site with a high level of cooperativity
(Blakely et al. 1993; Ringrose et al. 1998). The phosphoryl transfer and strand exchange
occurs within the central spacer or crossover region. The crossover sequence is
LEFT ARM RIGHT ARM
SPACER
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asymmetric and provides directionality to the site. The Cre recombinase does not require
any accessory factor to mediate recombination unlike more complex systems like λ-
integrase and XerC/D recombinases.
2.4. Mechanism of Cre mediated site-specific recombination.
The Int family of tyrosine recombinases of which Cre is a member and also the type 1B
topoisomerases are characterized by the presence of a conserved tyrosine nucleophile, an
active site structure and protein fold (Argos et al. 1986; Esposito and Scocca 1997;
Nunes-Duby et al. 1998; Sherratt and Wigley 1998; Cheng et al. 2000).
Fig.2. Mechanism of site-specific recombination. Two Cre proteins bind on either side of each of two
loxP sites, and then associate together, forming a synapse composed of two DNA molecules and four Cre
proteins. A tyrosine (Tyr) residue on opposite Cre proteins cleaves the DNA strand to which the proteins
are bound, forming two covalent 3’ phosphotyrosine bonds and two free 5’-hydroxyl ends. The free 5’-
hydroxyl ends in this Cre-DNA intermediate then react with the opposite phosphotyrosine bonds, yielding a
Holliday-type intermediate and regenerating native Cre proteins. Next, a tyrosine residue on the other two
                                                                                                                           Introduction
7
Cre proteins at the synapse cleave the DNA strands to which they are bound, again forming covalent 3’
phosphotyrosine bonds and free 5’-hydroxyl ends to give a second Cre-DNA intermediate. Finally, the free
5’hydroxyl ends of this intermediate attack the opposite phosphotyrosine bonds, yielding the recombinant
DNA products still bound to regenerated native Cre proteins. [Adapted from F. Guo, D. Gopaul, and G.
Van Duyne, 1997, Nature 389:40.]
As shown in Fig.2 the basic mechanism includes a first set of strand cleavage and ligation
producing a Holliday junction intermediate and this is then resolved by a second set of
strand cleavage and rejoining to yield recombinant products. The 8 bp asymmetric spacer
divides the loxP into two 13 bp domains, the left arm and right arm (Fig.1). The DNA
cleavages occur at the scissile sites between the first and second bases of the spacer, that
is between A and T of the top strand or between G and C of the bottom strand. The
interior six nucleotides are exchanged during the recombination reaction.
The main mechanistic features of the Int site-specific recombination mechanism have
been defined by crystal structures of Cre-lox complexes (Guo, Gopaul, and van Duyne
1997; Gopaul, Guo, and Van Duyne 1998; Guo, Gopaul, and Van Duyne 1999; Woods et
al. 2001; Martin et al. 2002; Ennifar et al. 2003). The crystal structures of the synaptic
complexes formed between a symmetric loxP site and two Cre mutants that are defective
in strand cleavage have revealed that the DNA bent sharply at end of the crossover or
spacer region and that the bend direction appeared to determine which of the stands in the
DNA duplex will be cleaved first (Guo, Gopaul, and Van Duyne 1999). There remains a
controversy regarding the order of strand exchange in Cre mediated recombination.
Analysis of in vivo recombination products suggested that cleavage was initiated on the
lower strand (Hoess and Abremski 1985), and this view was restated later (Lee and Saito
1998); (Lee and Sadowski 2001). On the other hand, strand composition analysis of the
Cre/lox Holliday junction intermediate revealed that Cre initiates recombination by
cleaving the upper strand at the scissile A residue at the left arm, and preferential
association of the cleaving or active Cre subunit to left arm dictates first strand exchange
and ensures productive orientation of loxP sites in the recombination synapses (Martin et
al. 2002). Recently two crystal structures of the full tetrameric Cre-loxP synaptic
complex has been reported (Ennifar et al. 2003). The pre-cleavage synaptic complex with
a phosphorothioate modification at the scissile bond also revealed a kink at the TG/AC
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residues in left side of the spacer next to the scissile ApT residues and they also showed
that the cleavage competent Cre subunit bound to the scissile ApT residues in the top
strand. Their studies suggested that the Cre induced kink activates the neighbouring
scissile phosphate for cleavage, a result contradictory to that of the Van Duyne lab which
proposed that bending at one-half of the spacer stimulates cleavage at the opposite half
(Guo, Gopaul, and Van Duyne 1999). The issue of spacer identity has been addressed in
an extensive mutational study (Lee and Saito 1998) and it was found that identity of the
innermost six bases was important for recombination though their findings suggested that
Cre cleaves the bottom strand first. Very recently experiments from the Van Duyne lab
(Ghosh et al. 2005) have addressed the issue of order of strand exchange in the context of
synaptic complex formed at the beginning of recombination pathway and have shown
through biochemical analyses that Cre preferentially cleaves the bottom strands of loxP
under conditions favouring synapsis, however, in absence of synapsis, top strand
cleavage also occurs but at a lower rate. The above studies reveal that there is a structural
basis for the observation that DNA strands are exchanged in a defined order although the
intricacies of Cre mediated recombination still remains a puzzle.
2.5. The spacer orientation determines the outcome of recombination.
The asymmetric spacer or core sequence confers directionality to the target site,
consequently the relative orientation of the target sites with respect to one another
determines the outcome of recombination. The possible recombination outcomes are
described in Fig.3.  Cre will excise a circular molecule from two directly repeated target
sites, invert the DNA between two inverted sites and exchange sequences distal to target
sites present on two linear molecules, such as a pair of non-homologous chromosomes.
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            Fig 3. The spacer orientation determines the outcome of recombination.
                                                                                                                           Introduction
10
2.6. Application of site-specific recombinases.
The Cre/loxP system is widely used for genomic manipulations as Cre efficiently
recombines loxP sites without the need for any accessory cofactors and have been used
effectively to create gene deletions, inversions, insertions and exchanges in exogenous
systems like mammalian cell culture and mice. The first indication that this phage
enzyme works in eukaryotic cells emerged from in vitro cell culture experiments (Sauer
and Henderson 1988; Sauer and Henderson 1990). These experiments were followed by
the demonstration that Cre works well in mice and also when expressed from a transgene
(Lakso et al. 1992; Orban, Chui, and Marth 1992). The excision reaction being
irreversible has been widely exploited and is the basis for conditional gene inactivation
and molecular fate mapping that has allowed gene function and cell deployment to be
studied in both embryos and adult stages.
1.Tissue-specific knockouts.
Traditional gene targeting strategy has two serious pitfalls. The first being that
elimination of the gene activity throughout the entire animal can result in early embryonic
lethality which precludes analysis of gene function at later stages and secondly the
maintenance of the positive selection cassette within the gene targeted can disrupt
neighbouring gene expression due to presence of regulatory elements in the selection
cassettes. These problems have been circumvented by employing site-specific
recombination to create knock out (KO) mice. In such studies, standard gene-targeting
techniques are used to produce a mouse in which an essential region of the gene of
interest is flanked by directly repeated loxP sites or floxed, so that tissue specific cre
expression results in inactivation of this allele. In most cases the loxP sites are placed in
introns, but some have also been placed in 5’ or 3’ flanking regions as well. Before
recombination the conditional allele should have wild- type activity. By crossing a mouse
line with a conditional allele to an effector mouse line expressing cre in a tissue-specific
manner, progeny are produced in which the conditional allele is inactivated only in those
tissues expressing cre. The first report of conditional gene modification examined the
effect of a null mutation in the essential polβ gene in T-cells (Gu et al. 1994). Since the
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first published results of the tissue-specific KO, the use of this strategy has steadily
increased and many diferent tissue-specific cre-expressing mice exist till date.
The presence of positive selection marker like neo can interfere with expression of the
floxed allele, compromising the wild type-activity in absence of recombination. This
problem had been solved by using three loxP sites such that both the gene of interest and
neo are floxed. A partial Cre mediated recombination event removes the neo gene, by
transiently introducing a cre expression cassette into ES cells (Gu et al. 1994). This can
also be achieved in vivo by injecting zygotes with cre expression cassette or by breeding
mice carrying the floxed allele to mice that mosaically express cre in the germ line
(Holzenberger et al. 2000a). Inclusion of the neo gene might generate a hypomorphic
allele which in combination with the null and conditional allele can be very informative
(Meyers, Lewandoski, and Martin 1998; Nagy et al. 1998). Apart from the tri-lox strategy
of removal of selection cassettes dual recombinase strategy has been used to create an
allelic series for Fgf8, where Fgf8 was floxed and neo cassette was flrted to allow for Flp-
mediated recombination (Meyers, Lewandoski, and Martin 1998).
2.Use of Cre in cell lineage analysis.
Reporter mice in which a histological marker is activated by Cre- mediated
recombination can be extremely useful in analyzing cell lineages. Examples of such
reporter mice are Cre-activable β-galactosidase (Mao, Fujiwara, and Orkin 1999; Soriano
1999)or the enhanced GFP (Mao et al. 2001) or EYFP and ECFP varieties (Srinivas et al.
2001) in the ROSA26 locus allowing constitutive transgene expression. Two well known
Cre reporter lines are the Z/AP (Lobe et al. 1999) and Z/EG (Novak et al. 2000) in which
Cre-mediated recombination causes a switch from lacZ  expression to alkaline
phosphatase or EGFP expression, respectively. Such reporter lines are useful for
molecular fate mapping studies as they represent a link between gene expression and the
fate of specific cell lineages. Fate mapping of mid-hindbrain border (Zinyk et al. 1998),
neural crest cell derivatives (Joseph et al. 2004), pancreatic islets (Herrera 2000) and
memory T cells (Jacob and Baltimore 1999) was achieved using this technique.
                                                                                                                           Introduction
12
3.Cre-mediated gene activation and tissue-specific gene repair.
Transgene activation by Cre-mediated recombination is achieved by removal of an
intervening ‘Stop’ sequence (Lakso et al. 1992), or by restoring an ORF that is
interrupted by floxed sequences. In such cases the remaining loxP sequence after
recombination must be tolerated as a part of the open reading frame.
Cre-mediated recombination can be used to achieve tissue- specific gene repair in a
design similar to that of a tissue-specific KO experiment. Human skin disorders have
been modeled in mice using this approach (Cao et al. 2001; Arin and Roop 2004). In
these studies mouse keratin genes containing point mutations as in human disease were
silenced by inclusion of a floxed neo gene. Topical application of an inducer of Cre
activity resulted in activation of the mutant allele and resulted in phenotypes similar to
that in disease syndromes.
4.Chromosomal rearrangements in mice to model human disease.
Chromosomal abnormalities are a principal cause of fetal loss and developmental
disorders in humans and chromosomal translocations are involved in the genesis of
human cancers. Chromosomal rearrangements in mice can thus be used to model these
disorders and genetically dissect their causes. The Cre/loxP recombination system has
been used to create mouse models to recapitulate human chromosomal rearrangements
(Buchholz et al. 2000; Collins et al. 2000). Mouse balancer chromosomes have been
developed using Cre/loxP technology by tagging chromosomal inversions with recessive
lethal mutations and coat colour markers (Zheng et al. 2000). Deletion chromosomes can
be engineered to provide segmental haploidy in the diploid mouse genome. Recessive
mutations induced in these deletions can be detected by crossing mutatnt mice to mice
hemizygous for different regions of the genome. It was possible to generate megabase
genomic rearrangements in mice by using chromosomal engineering technology
(Ramirez-Solis, Liu, and Bradley 1995).
Defined chromosomal deletions, duplications and inversions provide powerful tools for
mouse functional genomics. In vivo chromosomal engineering can be used to produce
genetic mosaics, defined as individuals heterozygous for a particular mutation, but
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containing patches of homozygous mutant cells, genetic mosaics are generated when
mitotic recombination occurs at G2 and is followed by X-segregation and clones of
homozygous mutant daughter cells are produced from heterozygous mothers. Genetic
mosaics allow assessment of effect of gene function on clonal cell lineages. Cre/loxP
technology was used to reproducibly induce mitotic recombination in mouse ES cells for
multiple allelic lox sites after transient cre expression (Liu, Jenkins, and Copeland 2002).
5. Application of Cre/loxP technology to recombineering.
Cre/loxP technology has also been combined with recombinogenic engineering or
recombineering techniques. Highly efficient phage based E.coli homologous
recombination systems have been developed which allows genomic DNA in BACs to be
modified and sub-cloned without using restriction enzymes and ligases (Zhang et al.
1998; Zhang et al. 2000). This strategy facilitates the introduction of target sites of
recombinases to be introduced into the mouse genome. Recombineering technique has
been employed to produce gene-targeting constructs to create conditional alleles in which
recombinase target sites are positioned at significant distances from each other (Liu,
Jenkins, and Copeland 2003; Testa et al. 2003).
2.7. Temporal control of recombinase expression.
The first inducible Cre mouse line used the Mx1 promoter, which can be activated by
injecting mice with interferon-α or β or with double-stranded RNA (poly-inosinic-
polycytidilic acid) (Kuhn et al. 1995). Such mice have been used to regulate gene
expression in the liver and immune system where recombination efficiency is high.
To add temporal control to site-specific recombinase activity, ligand regulated forms of
Cre and also Flp have been developed. A mutated estrogen receptor (ER) ligand binding
domain (LBD) has been fused to C terminus of Cre (Feil et al. 1996; Kellendonk et al.
1996) or Flp (Logie and Stewart 1995).
Currently there are three different ERs available, all of which are insensitive to
endogenous β-estradiol, but are responsive to the synthetic estrogen antagonist 4-hydroxy
tamoxifen. The ligand regulated switch for turning on recombinase activity has two major
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applications, first, broad expression of recombinase:ER fusions in most tissues to enable
temporal control of recombinase activity (Seibler et al. 2003), and secondly, tissue-
restricted expression of these fusions are achieved using specific enhancers (Logie and
Stewart 1995).
The C-terminus of Cre has also been fused to a mutated progesterone receptor (PR) LBD.
The fusion is responsive to the synthetic steroid RU486, but not to endogenous
progesterone (Kellendonk et al. 1996), however this system suffers from leakiness and
has been improved to confer lower background activity (Wunderlich et al. 2001).
A second mechanism to achieve temporal control of Cre or Flp expression involves the
tetracycline responsive system (Gossen and Bujard 1992). Inducing Cre expression with
Dox in the rtTA system results in a tighter regulation in comparison to tTA sysyem
(Utomo, Nikitin, and Lee 1999; Holzenberger et al. 2000b).
2.8. loxP variants.
Three loxP mutants, lox511, lox514 and lox 512 with single-base substitution in the
spacer region were investigated to understand how the asymmetric spacer region confers
directionality to the recombination reaction and the importance of spacer homology for
directionality. One of these mutants, lox511, was found to be incompatible in
recombination with wild-type loxP site and recombined only with like site.
Incompatibility is referred to the ability of a lox site to discriminate against recombination
with another lox site not sharing spacer region homology.
This study showed that most bases in the loxP core or spacer can deviate from the wild-
type as long as the cores match between recombining lox sites (Hoess, Wierzbicki, and
Abremski 1986). Minor changes in the pallindromic half –sites of loxP have also been
tolerated by Cre in several cases (Abremski and Hoess 1985; Abremski et al. 1988; Sauer
1992; Albert et al. 1995; Sauer 1996).  Further investigation of the functionality of cre on
mutant lox sites was carried out using 24 single-base substitution spacer mutants and 30
double-base substitution spacer mutants using in vitro recombination assays. The study
demonstrated the exclusivity of two loxP mutants, lox2272 and lox5171 with two-base
substitutions, showing efficient recombination among themselves but not cross
recombination with loxP site (Lee and Saito 1998).
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There are two classes of mutations in the loxP variant sites that can alter the specificity
and directionality of recombination reaction. The first class are the spacer variants. As
discussed above spacer region homology is important for efficient recombination
between directly repeated lox sites in cis. Crystallographic studies of Cre recombinase
bound to lox site suggest that base pairing is required between exchanging strands in the
recombination complex for efficient recombination (Guo, Gopaul, and van Duyne 1997).
The spacer region not only confers directionality but also specificity to recombination
reaction. The second class of lox mutations are within the 13 bp palindromes or inverted
repeats, two sites lox71 and lox66 are examples of such inverted repeat variants.
Mutations within the pallindromic arms weaken the affinity of recombinase for its
binding site. Recombination between lox sites with mutations in complementary
pallindromic arms generates a wild type loxP site and a site with doubly mutant arms.
This double mutant no longer serves as a recombination substrate and undergoes no
further recombination. This kind of recombination reaction between pallindromic lox
mutants is almost exclusively unidirectional. The lox sites containing arm mutations have
been used to stably integrate plasmid DNA to both plant and mammalian chromosomes
(Albert et al. 1995; Araki, Araki, and Yamamura 2002).
2.9.  Applications of loxP variants in genome engineering.
Recombinase-mediated cassette exchange.
Recombinase-mediated cassette exchange (RMCE) is a method to achieve site-specific
chromosomal integration at a defined genomic locus. The findings that Cre can tolerate
variations in its target sites led to the development of RMCE.
RMCE can be defined as a site-specific recombination reaction that entails the exchange
of one DNA cassette for another. It is a two-step procedure. Heterospecific or
incompatible lox sites are targeted to the genomic locus of interest by homologous
recombination. Action of recombinase inserts a replacement sequence into this pre-tagged
site by double reciprocal crossover. Such a method permits re-iterative modification of a
particular genomic locus. This insertion reaction exploits the fact that recombination is
efficiently mediated between pairs of homotypic, but not heterotypic target sites.
Normally a selectable marker flanked by heterospecific lox sites is inserted into a
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chromosomal site, then a DNA sequence of choice is inserted into the tagged site by
replacing the selectable marker in presence of the recombinase. Mechanistically this
process involves two recombination events, an integration step followed by an excision
step, leaving heterotypic target sites flanking the exchanged cassette. In RMCE reactions
the target sites may be directly or inversely oriented. The advantage of using inverted
sites is that cassette excision is prevented should there be promiscuous recombination
between pair of heterotypic target sites. RMCE has been adapted to create isogenic cell
lines (Bouhassira, Westerman, and Leboulch 1997; Feng et al. 1999; Kolb 2001).
Though RMCE proved to be very efficient in bacteria and cell culture, the system suffers
from promiscuous recombination between heterospecific target sites leading to deletion
of floxed cassette.
 Fig.4.  Schematic representation of RMCE. L1 and L2 are a pair of hetero-specific target sites flanking a
chromosomally integrated cassestte cas1 to be exchanged with the incoming cassette cas2 flanked by the
same pair of sites. Recombination through either L1 or L2 followed by recombinant resolution results in the
exchange of chromosomally integrated cas1 by incoming cas2.
The re-excision can be prevented by using inverted target sites, but this requires
additional screening to determine the orientation of the exchanged gene. This procedure
enabled studies on the orientation dependence of expression parameters at a given
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genomic site. Three sites investigated in this way displayed either stable or silencing
position effects and demonstrated that a transgene at a given genomic locus can be
differentially imprinted depending on its orientation (Feng et al. 2001).
 FLEx switch.
Another very recent use of mutant lox511 and wild type loxP site was in a novel strategy
called FLEx switch (Schnutgen et al. 2003). The strategy uses the ability of Cre to both
invert or excise DNA depending on the orientation of the target sites. This Cre-dependent
genetic switch works in a manner such that the expression of a given gene is turned off
while the expression of another gene is concomitantly turned on. Stable DNA inversion
can be achieved using this strategy, it also involves two recombination events like
RMCE, the first is inversion followed by an excision step. The final product can serve as
a substrate for subsequent rounds of RMCE.
To broaden the applicability of Cre recombinase, directed evolution strategies have been
used to change the substrate specificity of Cre.
2.10. Directed molecular evolution.
Directed molecular evolution is the laboratory approach to Darwinian evolution and is a
powerful tool for exploring and altering enzyme functions. The process is an algorithm of
mutation, recombination and selection and has been widely applied industrially to
redesign a myriad of protein properties including thermal and solvent stability, enzyme
selectivity, solubility and protease susceptibility. Another approach to enzyme
engineering is to make specific modifications which requires a detailed and often
unattainable understanding of sequence and function and this can be bypassed by directed
evolution.
One of the most important aspects of a directed evolution experiment is the construction
of the diverse molecular libraries of enzyme variants. The methods of choice for creation
of molecular diversity are error-prone PCR, oligonucleotide-directed randomization and
in vitro recombination.
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Random mutatgenesis of the whole gene is the most straightforward approach for library
construction and requires no structural or mechanistic information while uncovering
potentially beneficial mutations.  Error-prone PCR followed by sequential rounds of
screening and selection of improved variants has been used to realize wide number of
engineering goals, like creation of enantioselective enzymes like cyclohexane
monooxygenases (Reetz et al. 2004). Error-prone PCR was also used to enhance the
selectivity of cytosine deaminase designed for killing tumor cells (Mahan et al. 2004), for
increased activity of cytochromes 450 which are important for the metabolism of drugs
and other xenobiotics (Kumar et al. 2005).
The most dramatic results in the field of directed evolution were achieved by using in
vitro recombination methods to enrich diversity by exploring much larger sequence
space. DNA shuffling pioneered by Stemmer (Stemmer 1994) is a method for in vitro
homologous recombination of pools of selected mutant genes by random fragmentation
and PCR reassembly (Fig.5).
Staggered extension process or StEP is another shuffling format which uses PCR based
recombination with very short annealing or extension cycles (Zhao et al. 1998). Full
length chimeric genes are created when fragments denatured from parent templates
switch to a new template based on high homology. Due to template switching the
growing polynucleotides contain sequence information from different parental genes and
the resulting progeny has multiple crossovers from parent templates.
Recently several modifications of DNA shuffling have been reported. Exon shuffling
(Kolkman and Stemmer 2001), family DNA shuffling (Crameri et al. 1998), sequence-
homology-independent protein recombination or SHIPREC (Sieber, Martinez, and
Arnold 2001). Other homology dependent recombination methods have been developed
like degenerate homoduplex recombination for engineering a variety of mammalian
epidermal growth factors (Coco et al. 2002), synthetic shuffling (Ness et al. 2002) and
assembly of designed oligonucleotides (Zha, Eipper, and Reetz 2003). In these methods
overlapping oligonucleotides encoding all the degeneracy in two or more parental genes
are used in a PCR reassembly reaction. The result is a library where all the shuffled
variants are equally likely regardless of linkage.
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   Fig.5. Schematic representation of DNA shuffling strategy.
Homology independent structure guided methods have also been developed. Sequence-
independent site-directed chimeragenesis (Hiraga and Arnold 2003) is a method where
semi-rationally designed peptide building blocks are shuffled. The method relies on a
structure based computational predictor SCHEMA which defines peptide fragments from
parental proteins which can be interchanged with minimum structural interference.
Recently SCHEMA guided recombination of three cytochromes P450 was used to create
chimeras of properly folded novel P450 proteins (Otey et al. 2006).
Apart from library diversity, a lot of focus is also been given to in vitro selection of novel
enzyme variants. In vitro compartmentalization (IVC) using a water-in-oil emulsion has
emerged as a promising alternative for selecting catalysts (Tawfik and Griffiths 1998;
Doi and Yanagawa 1999; Griffiths and Tawfik 2003).
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Therapeutic proteins like IFN-αs (Chang et al. 1999b), high affinity antibodies (Boder,
Midelfort, and Wittrup 2000; Hanes et al. 2000), protease inhibitors like plasminogen
activator inhibitor-1 (Stoop et al. 2001) have also been engineered using directed
evolution and shuffling techniques. Besides engineering of gene therapy vehicles has also
been achieved (Soong et al. 2000) through DNA family shuffling of envelope genes of
MLVs for developing new tropism for CHO cells.
2.11. Directed evolution of Cre variants.
Applications of Cre are currently restricted by the requirement of appropriately
positioned loxP sites in the targeted DNA regions. The ability to target for new target
sites different from a canonical loxP would significantly increase the use of Cre. A
number of groups have developed protein evolution strategies to manipulate the
enzymatic properties of Cre to create new recombinase variants (Buchholz and Stewart
2001; Rufer and Sauer 2002; Santoro and Schultz 2002). Such studies were aimed at
changing the target specificity of Cre to broaden the applicability of the recombinase to
novel targets and also to get a better understanding of the mechanism of site-specific
recombination and represent a step towards the custom evolution of recombinases that
recognize unique sites within the mammalian genome.
A Flp recombinase variant with enhanced thermostability, Flpe, was generated from a
randomly mutagenised library of Flp coding sequence using successive rounds of
screening and DNA shuffling (Buchholz, Angrand, and Stewart 1998). Flpe exhibits
about four fold higher recombinase activity in cell culture compared to wild type and is
also used to mediate efficient recombination in mice (Farley et al. 2000; Rodriguez et al.
2000; Awatramani et al. 2003). Flp variants with an altered target site (mFRT) specificity
has also been generated using a dual reporter screen in E.coli (Voziyanov, Stewart, and
Jayaram 2002). Besides Flp and Cre, another site specific recombinase, the phage φC31
integrase was subjected to directed evolution using two cycles of shuffling and screening
in E.coli to obtain evolved integrases with better sequence specificity and integration
frequency at a pseudo attP sequence on human chromosome 8 (Sclimenti, Thyagarajan,
and Calos 2001).
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Such directed evolution strategies can be further used to expand the recombination
repertoire of Cre and related recombinases for important practical applications in genome
manipulations.
2.12. Aim of my work.
Site-specific recombinases like Cre have proved to be highly efficient tools for genomic
manipulations. The Cre recombinase favours excision over integration as the product of
integration becomes a substrate for re-excision if recombinase activity is still around. In
fact most of the genomic manipulation strategies developed exploit the virtually
irreversible excision recombination mediated by Cre. The efficiency of Cre mediated site-
specific recombination has been used in a wide variety of exogenous systems like
mammalian cell culture, mice, flies and zebrafish.
Retroviruses like HIV-1 integrate into the host chromosome and persist as a provirus
flanked by viral long terminal repeats or LTRs. Establishment of the provirus is an
obligatory step in the retroviral life-cycle and serves to maintain viral sequences in the
infected cell. The LTRs of proviral DNA direct the expression of viral genes. A
molecular strategy to excise the proviral DNA from infected cells could be envisioned by
applying the principle of site-specific recombination mediated through sequences in the
flanking LTR repeats of the pro-viral genome. The Cre/lox system has been indicated as a
possible antiviral strategy against retroviruses (Flowers et al. 1997; Lee and Park 1998).
A modified Cre recombinase recognising sequences within each LTR of proviral DNA
could mediate excision of the viral coding sequences eliminating the intact provirus and
represents a novel direct antiviral strategy targeting the provirus. To realize the potential
of a genetic surgery targeting an integrated provirus, it is essential to determine whether
such a recombinase can actually be generated that can recombine a sequence within a
retroviral LTR. The laboratory evolved Cre recombinase variants with altered site-
specificity have proved that it is possible to generate tailored recombinases and hold
promise for increasing the applicability of these recombinases. Directed evolution has
developed into a mature technology and can be used to engineer solutions for the
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development of human therapeutics and generate new protein variants that exhibit traits
never observed before. To maximize the utility of evolved recombinases it is essential to
demonstrate the feasibility of directing evolution towards more variant and asymmetric
target sites.
The aim of my work has been to use directed evolution to generate a custom designed
novel Cre recombinase recognizing an asymmetric sequence within an HIV-l LTR,
investigate the recombination efficiency of this novel recombinase in bacteria and
mammalian cells and provide proof of principle that the applicability of such evolved
enzymes could be further extended for therapeutic anti-retroviral DNA surgery.
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3. Abbreviations.
Amp     Ampicillin
Ara     L-Arabinose
CAT    Chloramphenicol acetyl transferase
Cm      Chloramphenicol
Cre      Bacteriophage P1 encoded site-specific recombinase
DIG      Digoxigenin
DMEM Dulbecco’s modified Eagles medium
dNTP  Deoxyribonucleotide triphosphates
dUTP    Deoxyuridine triphosphate
FCS      Fetal calf serum
IRES    Internal ribosome entry site
Kb      Kilobase pairs of DNA
Loxltr   HIV-1 LTR derived target sequence
LoxP    Cre recombinase recognition target sequence
LTR   Long terminal repeat
 Luc     Luciferase
 µg/ml  microgram/mililitres
 µl        microlitres
OD       Optical density
PAC      Puromycin acetyl transferase
PBS       Phosphate buffered saline
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Pen-strep   Penicillin-streptomycin for use in mammalian cell culture medium
SDS          Sodium dodecyl sulphate
X-gal     Histochemical reagent for detection of Beta galactosidase activity,
               (5-Bromo-4-Chloro-3-Indolyl-β-D-Galactopyranoside).
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4. Materials and Methods
4.1. Enzymes, chemicals, reagents and kits.
All restriction enzymes, T4 DNA ligase ligase and Calf intestinal alkaline phosphatase
were purchased from New England Biolabs (NEB), USA.
Taq DNA polymerase, Deoxyribonucleotides (dNTPs), 10X PCR buffer and MgCl2 was
purchased from Bioline.
Agarose was purchased from Invitrogen Life Technologies.
All cell culture reagents, that is DMEM, FCS, Pen-Strep and Trypsin were purchased
from Gibco. Puromycin was purchased from Invivogen and Geniticin was purchased
from Gibco.
 Qiagen’s Effectene transfection reagent was used for all transfections.
DNA isolation was performed with Qiagen’s QIAprep Spin Mini-prep Kit and Qiagen
Plasmid Maxi Kit.
Genomic DNA from Hela cells was isolated with QIAamp DNA Blood minikit.
Gel extraction and PCR purification was performed with QIAEX11 gel extraction Kit
(Qiagen) and QIAquick PCR purification kit (Qiagen).
X-Gal was purchased from DiagnosticsChemicals Limited, Charlottetown, PEI.
L-arabinose was purchases from Sigma-Aldrich.
LB liquid bacterial medium and LB-agar plates were provided by the institute kitchen.
4.2. Synthetic oligonucleotides
All the oligonucleotides in this work were ordered from Biosprings, Germany.
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4.3. Bacterial strain
 For all purposes the strain E.coli DH5α (F'phi80dlacZ delta(lacZYA-argF)U169 deoR
recA1 endA1 hsdR17 (rk-, m k+) phoA supE44lambda-thi-1 gyrA96 relA1/F' proAB+
lacIqZdeltaM15 Tn10(tetr) was used.
4.4. Plasmids
1). Evolution vector pEVO.
This plasmid is based on the pBAD33 vector (Guzman et al. 1995) and contain two
directly repeated recombinase target sites (loxP or loxltr and loxltr subsets). The plasmid
allow arabinose induclible expression of the recombinases which can be efficiently
repressed with glucose in E.coli. The recombinases are expressed by the araC promoter.
The plasmid offers convenient cloning of the recombinases using BsrG1 and Xba1 sites
flanking the recombinase coding region, and also cloning of directly repeated lox sites by
using flanking Bgl11 restriction sites. The map of the vector is shown in Fig.6a.
2). PSVpaX and PSVloxltr reporter vectors.
The pSVpaX and pSVloxltr are multihost reporter vectors. They are recombinase
excision reporter plasmids for use in both mammalian cells and E.coli. Monitoring of
lacZ activity allows easy detection of recombination. In bacteria, recombination at the
target lox sites results in removal of a promoter within the puromycin acetyl transferase
(pac) gene that results in prevention of lacZ expression and renders white colonies on X-
Gal plates. In mammalian cells, recombination turns on lacZ expression by removal of
the 1.1 kb pac region.
The pSVpaX and pSVloxltr are identical except for the directly repeated loxP or loxltr
sites flanking the pac region, respectively. The map is shown in Fig. 6b.
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3). Mammalian recombinase expression vectors.
This group of expression plasmids were available commercially from Clontech. The
expression cassette contains the human cytomegalovirus major immediate early
promoter/enhancer, a synthetic intron known to enhance the stability of the transcript, an
ECMV IRES followed by an antibiotic resistance marker. The IRES facilitated the
expression of the selection marker (Fig.6c). The unoptimised Tre recombinase was
cloned into the hygromycin version of the vector by using BsrG1/Nhe1 sites in the MCS,
and the optimized hTre was cloned into neomycin version of the vector by using Nhe1
and BamH1 sites in the MCS of the vector (Fig.6d).
4).  HIV-1 HXB3 based reporter vectors (from J. Hauber lab, HPI, Hamburg).
These vectors contain the HIV-1 HXB3 long terminal repeat, which drives the expression
of a downstream reporter gene. The 5’ long terminal repeat has the TAR binding site
where Tat protein binds and transactivates reporter genes. The loxltr sequence was cloned
within the long terminal repeats of the vector. The HIV_T2_LUC and HIV_T1_LUC
contain the firefly luciferase as the reporter gene, and the HIV_T2_CAT has the
chloramphenicol acetyl transferase as the reporter gene (maps shown in Fig.26 and
Fig.28). The HIV_T2_CAT stable Hela cell lines were also provided by the Hauber Lab.
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(a).
(b).
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(c).
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Fig. 6 Vectors used in this project.
(a). Evolution vector pEVO.
(b) Reporter vector used for recombination assay in Hela cells. The psvpaX vector is the same except for
presence of loxP sites in place of loxltr. P1 and P2 represent the primer pairs used to assay for
recombination in Hela cells.
(c) Recombinase expression vectors used in Hela cells.
4.5. Construction of pEVO-loxltr vectors and psvloxltr vectors.
A 690 base pairs fragment flanked by loxltr sites was constructed by using
oligonucleotides:
(5’ATGAGATCTACAACATCCTATTACACCCTATATGCCAACATGGAAGCTTGCATGCCTGCA
GATCGAG-3’)
(5’TTGAGATCTCCATGTTGGCATATAGGGTGTAATAGGATGTTGTTCGAACTGTACCGGTT
GTTAGTGA-3’) using the pEVO-loxP vector as a template.
The design of the oligos were designed that the resulting fragment would be flanked also
by Bgl11 sites.  The PCR fragment was digested with Bgl11 and CIP and cloned into
similarly digested pEVO vector. Clones were sequenced using the primer (5’-
CAATAACCCTGATAAATG-3’). All the loxltr subset vectors were also constructed in a
similar fashion.
The psvloxltr reporter vector was constructed in a two-step method using psvpaH as a
template. The first loxltr site was cloned in place of the loxH site by using oligos (5’-
ACAACCGGTACAGTTCGAACAACATCCTATTACACCCTATATGCCAACATGGAAGCTTGCATG
CCTGCAGGTCGGCCGCCACGACCGG-3’) and
(5’-TTCGACGCTCTCCGGCGT-3’). BstB1/Sac11 sites were used for cloning and correct
clone verified by sequencing. The second loxltr site was cloned by using primers (5’-
GTCTGGATCCACAACATCCTATTACACCCTATATGCCAACATGGACCGGGCCACCATGGTC
GCGAGT-3’) and (5’-TCATCGATAATTTCACC-3’) and using BamH1 and Cla1 sites for
cloning.
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4.6. Preparation of recombined versions of psvloxltr and HIV_T2_CAT
vectors
The pEVO-loxltr-Tre25 recombinase was digested with Sac1 and Xba1 and was cloned
into the similarly digested pBAD33-Cre vector. The resulting pBAD-Tre25 (Cm
resistant) vector was used to prepare chemically competent cells with recombinase
expression induced with 100µg/ml L-arabinose. These cells are transformed with the
reporter vectors (psvloxltr or HIV_T2_CAT, both Amp resistant) and recombinase
induced with the same arabinose concentration and grown for 2 hours at 37°C. Then a
part of the cells are plated onto Ampicillin (100µg/ml) containing LB-agar plates and the
rest of the cells are cultured overnight in LB containing Chloramphenicol (25µg/ml) and
Ampicillin (100µg/ml) and 100µg/ml of L-arabinose. Plasmid DNA was isolated from
the overnight culture and transformed into E.coli DH5α competent cells. The culture was
plated onto ampicillin LB agar plates. Random colonies were picked up and restreaked
on Cm Plated to segregate the recombinase plasmid from the recombined reporter
plasmids.
4.7. DNA shuffling and cycling.
DNA shuffling was carried out to recombine the obtained Cre mutants in vitro. The basic
protocol was according to Stemmer (Stemmer 1994). DNA fragments containg the Cre
gene or mutant libraries were randomly fragmented by sonication using 12% amplitude
for 5 minutes with 30s pulse on and 5s pulse off. After every third cycle the libraries were
shuffled, for instance the third library was shuffled by mixing 3 parts of library 3, 2 parts
of library 2 and 1 part of library 1. The sonicated fragments (100-500 bp in size) were
purified by the PCR purification kit from Qiagen. To reassemble the fragments 10µl of
the sonicated DNA was added to a 50µl PCR mix containing 1X PCR buffer, 250µM of
each dNTP, 3mM of MgCl2 and 1.5units of BioTaq DNA polymerase and amplified
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according to the following program: 35 cycles of 94°C, 60s; 55°C, 60s; 72°C, 90s. Three
microlitres of this primerless PCR reaction product was used as a template for the next
PCR with primers P1 (5’-TCTACTGTTTCTCCATA-3’) and P2 (5’- GCGGATGAGAGAAGATT-
3’) in a 50µl PCR mix with the same cycling conditions. The shuffled library was
digested with BsrG1 and Xba1 and recloned into a similarly digested pEVO vector used
for directed evolution.
Plasmid DNA isolated after each evolution cycle was digested with Nde1 and amplified
with the same PCR conditions as stated above using primers P1 and P4 (5’ -
TGTCGCCCTTATTCCCT-3’), digested with BsrG1 and Xba1 and subcloned into similarly
digested pEVO. The resulting recombinase libraries were transformed into E.coli DH5α
chemically competent cells and grown in LB liquid culture containing chloramphenicol at
a concentration of 25µg/ml and L-arabinose to induce recombinase expression.
4.8. Cell culture
Hela cells were cultured at 37°C under 5% CO2 in DMEM containing 100 units /ml of
penicillin and streptomycin and supplemented with 10% FCS.
Puromycin resistant psvpaX and psvloxltr reporter cell lined were obtained by
transfection of 2X106 cells in a 10cm dish with 8µg of the reporter plasmids using
Effectene transfection reagent (Qiagen) according to the manufacturer’s instructions, and
selection with the antibiotic was started 48 hours post transfection. The final stable clones
were grown in presence of 3µg/ml of puromycin (Invivogen).
4.9. Transient assays for measurement of β-galactosidase activity
Hela cells were transfected with a 1:2 ratio recombinase expression plasmids and lacZ
reporter plasmids in 6-well format by using Effectene transfection mix. A total of 0.6µg
of DNA was used for transfections. Parallel transfections with recombined version of the
reporter plasmids were carried out to express the final enzyme activity as a percentage of
total activity in recombined reporter plasmids. Relative β–galactosidase activities were
measured 48 hours post transfection using the Tropix Galacto-Light kit (Applied
Biosystems, Bedford, MA) according to manufacturer’s protocol. Recombination
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efficiencies were corrected for total protein content in the cell lysate measured by BCA
protein assay kit (Pierce, Rockford, IL).
The loxltr stable cell lines were transfected with 0.8µg with either mock, Cre or Neo-hTre
plasmids using Effectene and were assayed for β–galactosidase activities 48 hours post
transfection using Galacto-Light. The β–galactosidase activities were corrected for
transfection efficiencies by measurement of renilla luciferase activity using assay kit from
Biotium, Hayward, CA.
4.10. X-Gal staining of Hela cells
Hela cells were analysed for recombination and expression of β–galactosidase by X-Gal
staining. The cells were washed with PBS 48 hours post-transfection, and fixed with 2%
formaldehyde and 0.1% glutaraldehyde, permeabilized with 0.5%TritonX100 and stained
overnight at 37°C with staining solution containing 1mg/ml X-gal, 2mM MgCl2, 5mM
potassium ferricyanide and 5mM potassium ferrocyanide.
4.11. PCR analysis of recombination in stable reporter Hela cell lines.
Stable loxltr and loxP Hela cell lines were transfected in 10 cm format with respective
recombinase expression vectors using Effectene. Transfected cells were washed with PBS
after 48 hours, and trypsinised. Hela genomic DNA was isolated using QIAamp DNA
Blood mini kit (Qiagen) according to the manufacturer’s instructions. Genomic DNA
(3µg) was analysed for recombination by using primers P1 (5’-
GCCTCGGCCTAGGAACAGT-3’) and P2 (5’- CCGCCACATATCCTGATCTT-3’) using the PCR
program 30 cycles of 95°C, 30s; 62°C, 30s; 72°C, 40s in a 50µl PCR reaction containing
1X PCR buffer, 250µM of each dNTP, 3mM of MgCl2 and 1.5units of BioTaq DNA
polymerase. The PCR products were visualized on a 0.7% agarose gel.
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4.12. Southern analysis
10µg of Hela genomic DNA was electrophoresed in a 0.7% agarose gel. The DNA
containing gel was depurinated using 250mM HCL for 20minutes, followed by
denaturation in 0.5MnaOH, 1.5M NaCl for 15 minutes, twice, and finally neutralized
with 0.5M Tris-Hcl (pH7.5), 1.5M NaCl for 15 minutes twice. The gel was then shortly
equilibrated in 20XSSC, before overnight blotting onto a nylon membrane by capillary
transfer in 20XSSC. After transfer, the membrane was UV crosslinked. After crosslinking
the membrane was washed in water and air-dried followed by 2 hour long
prehybridisation in buffer containing DIG Easy Hybridization granules (Roche
Diagnostics, Germany). A DIG-dUTP labeled DNA probe hybridizing to the lacZ region
in the psvpaX or psvloxltr reporter plasmids was synthesized using PCR DIG Probe
Synthesis Kit (Roche Diagnostics, Germany) according to the manufactures’s
instructions. After prehybridization, the membrane was hybridized overnight at 50°C in
prewarmed hybridization buffer prepared from DIG Easy Hyb Granules and containing
2µl probe /ml hybridization buffer. Hybridization was also carried out by using RNA
probe synthesized using DIG RNA labeling mix (Roche Diagnostics, Germany). After
hybridization, the membrane was washed in low stringency buffer (2XSSC, 0.1%SDS)
three times for 5 minutes each at room temperature, followed by washing in high
stringency buffer (0.5XSSC, 0.1%SDS for DNA probe and 0.1XSSC, 0.1%SDS, for
RNA probe), at 68°C twice for 15 minutes each.
After stringency washing, the blot was subjected to immunological detection using an
anti-digoxigenin antibody conjugated to alkaline phosphatase (Roche Diagnostics,
Germany) and chemiluminescent substrate CDP-Star (Roche Diagnostics, Germany).
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4.13. Transient Tat transactivation assays using luciferase reporter vector
and CAT reporter vector
Hela cells were transfected in 12 well format using Effectene transfection reagent for Tat
activation assay with luciferase reporter vectors. The transfection mix contained 0.16µg
HIV_T2_LUC or HIV_T1_LUC expressing firefly luciferase, 0.16µg of pIres-neo-hTre
recombinase vector or the empty vector as negative control, 0,08µg of the Tat vector or
pcDNA3 as negative control for Tat. The cells were lysed 48 hours post transfection and
assayed for firefly luciferase activity by using Firefly and Renilla luciferase assay kit
(Biotium, Inc., Hayward, CA). The activities were corrected for transfection efficiency by
using psvΔpax vector as an internal control and measuring the β-galactosidase activity
from the cell lysates.
The Tat activation assay with the HIV_T2_CAT vector was carried out in a similar
manner. Transfections were carried out in 6-well format by using 0.2µg of the CAT
vector, 0.4µg of the pIres-neo-hTre vector or the empty vector as negative control and
0.2µg Tat vector or pcDNA3 as negative control for Tat. The transfected cells were lysed
48 hours post transfection and the CAT activity was measured using the CAT ELISA kit
(Roche Diagnostics, Germany) according to manufacturer’s instructions. PCR analysis of
recombination was carried out in Hela cells transfected with the HIV reporter vectors in
presence or absence of the recombinase, using primers L1 (5’-
GAAGGTGGGTTTTCCAGTCA-3’) and L2 (5’- AGGGAAGAAAGCGAAAGGAG-
3’) using the PCR program program 30 cycles of 95°C, 30s; 60°C, 30s; 72°C, 40s in a
25µl PCR reaction containing 1X PCR buffer, 250µM of each dNTP, 3mM of MgCl2 and
1.5units of BioTaq DNA polymerase. The PCR products were visualized on a 0.7%
agarose gel. The PCR products were gel extracted and purified using Gel extraction kit
(Qiagen) and sent for sequencing.
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5. Results
The sequence specific manipulation of DNA by Cre recombinase represents a powerful
approach to studying gene function. The relatively simple biochemical requirements of
Cre, the very high sequence specificity towards loxP sites and the fact that Cre can
mediate recombination both in prokaryotes and eukaryotes have contributed to the
development of elegant strategies for genomic manipulations and Cre has been
successfully used for conditional mutagenesis, gene replacement and deletion and
chromosome engineering experiments (Nagy 2000; Sauer 2002). Applications of Cre
however require appropriately positioned loxP sites in the targeted DNA regions. The
ability to target for new target sites different from a canonical loxP would significantly
increase the use of Cre. In the recent years several groups have applied directed evolution
to generate Cre variants recognizing novel target sites (Buchholz and Stewart 2001; Rufer
and Sauer 2002; Santoro and Schultz 2002).  Such studies represent a step towards the
custom evolution of recombinases recognising unique sites within mammalian genomes
and serve as a useful starting point for the directed development of recombinases
recognizing distinctly non-lox targets. To maximize the utility of evolved recombinases it
is essential to demonstrate the feasibility of directing evolution towards more variant and
asymmetric target sites and requires detailed study of the applied properties of such
recombinases and their applications for therapeutic purposes.
5.1. Selection of a sequence from an HIV-1 LTR as a novel target site for
directed evolution.
The first requirement was to select an HIV-1 LTR sequence with optimum sequence
similarity to loxP, to facilitate the evolution process. A prerequisite for any directed
evolution experiment is the detection of some amount of desired activity in the starting
library, as the mutations in a library made by whole gene random mutagenesis has limited
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diversity which is unlikely to increase the activity more than a factor of two (Moore and
Arnold 1996).
 We looked for sequences within the long terminal repeats (LTRs) of HIV-1 genomes.
Several HIV-1 LTR sequences were scanned for similarities to the canonical loxP site.
Among all the LTR sequences scanned, the sequence having the maximum sequence
identity to loxP was selected as the novel target site to direct evolution of Cre and was
termed loxltr. The sequence belonged to the 695 bp 5’ LTR DNA of HIV-1 strain
TZB0003 (locus AF096641) from Tanzania and is part of the modulatory U3 region of
the LTR. The U3 region of an HIV-1 LTR is normally around 450 base pairs and contains
mostly of cis-acting DNA elements, which are binding sites for cellular transcription
factors. The selected loxltr site is a 34 bp asymmetric sequence and has 50% sequence
similarity to loxP with four bases mismatch in the left element and six in the right
element and a completely different spacer (Fig.7).
 Fig.7.The selected loxltr sequence. The bases in bold represent those different from loxP, the red
sequence represents the left element or left half-site and the green the right element or right half site. The
8bp spacer sequence is underlined for loxltr.
5.2. Directed evolution strategy to generate loxltr specific recombinase.
Once the target site was selected, it was necessary to direct the evolution of Cre
recombinase using an evolution strategy to create a variant recognizing the loxltr
sequence.
A PCR based evolution strategy, substrate linked protein evolution (SLiDE) had been
previously used successfully to generate Cre variants, which recognise and recombine a
sequence chosen from the human chromosome 22, termed loxH (Buchholz and Stewart
2001). SliDE incorporates an important feature of directed RNA evolution in that there is
physical linkage between the coding molecule undergoing evolution and the target.
                                                                                                                                    Results
38
The evolution vector used in SliDE is termed pEVO and is a single vector in which both
the recombinase coding region and its target lox sites are present. The recombinase
expression is regulated by an arabinose inducible promoter (the details of this vector are
given in the Materials and methods section and Fig.6a). The vector is so designed that the
downstream target sites flank an intervening region of around 700 bp which contain an
Nde1 cleavage site.
The presence of the recombinase coding region and its substrate (target sites) on the same
vector ensures that upon expression of the recombinase, its action would alter the
substrate only upon successful recombination and lead to a deletion of the intervening
region between the target site pair resulting in the loss of the Nde1 site, and a PCR using
primer pair P1 and P4 (as shown in Fig.8) would selectively amplify only those
recombinases which produce the desired change in the substrate from a whole library of
recombinase variants. In this way large libraries can be conveniently screened and
successful recombinase coding regions can be rapidly retrieved. The evolution cycle
begins with cloning the recombinase or their mutated libraries into pEVO along with the
required target sites. This vector is then transformed into E.coli, and recombinase
expression induced with arabinose. After overnight culture the plasmids are harvested
from the pool, digested with Nde1 and then PCR amplified with the primers P1 and P4
specified in Fig.8. The PCR product of the recombined form of the plasmid produces a
1.7 Kb band. The strategically placed restriction site ensures that plasmids not
recombined are linearised by Nde1 and rendered unsuitable for PCR amplification thus
removing the unsuccessful candidates from the pool. The PCR product is digested by
BsrG1 and Xba1 and the successful recombinase coding sequences is subcloned back into
the vector for the next cycle. Using E.coli for the evolution process reduces the time-scale
of each cycle and also favours easy evaluation of the efficiency of evolution process. I
decided to use this strategy for in vitro evolution of a loxltr- specific recombinase owing
to the ease, reproducibility, technical simplicity and the availability of all required
resources and vectors in my lab.  Fig.8 gives a schematic description of the evolution
strategy.
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                   Fig.8.  Schematics of Substrate linked directed evolution or SliDE.
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5.3. Getting started with in vitro evolution.
The pEVO vector permits a qualitative and easy analysis of the extent of recombination
by a BsrG1-Xba1 digest of the vector carrying the recombinase and its target sites. A 4.2
Kb band appears as a result of recombination which deletes the intervening DNA
between the target lox sites. Intensity of this band reflects the extent of recombination in
comparison to unrecombined upper band of 4.9 Kb. Using the pEVO-loxP-Cre vector as
an example, recombination at loxP was evident even in absence of induction, an almost
complete recombination occurred at an induction with 10µg/ml L-arabinose (fig.9).
Fig.9. Cre mediated recombination at loxP in E.coli.. BsrG1 and Xba1 digest of pEVOloxP-Cre
plasmids in presence (10 µg/ml) and absence of arabinose induction. The lower band of 4.2 Kb represents
the recombined band.
The loxltr sequence was cloned into the pEVO vector in place of loxP by using oligos
(described in materials and methods section) to generate the pEVO-loxltr vector. Firstly
wt Cre was cloned into this vector to create pEVO-loxltr-Cre, transformed into E.coli
DH5α, and recombinase expression induced with high concentration of arabinose
(200µg/ml). Recombination at the new loxltr target sites would lead to a deletion of 690
bp of intervening DNA between the two sites. An Nde1 digestion would remove the un-
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recombined vectors and subsequent PCR would produce a 1.7 kb band reflecting
recombination. However Cre failed to recombine the loxltr sites and no PCR product was
obtained (data not shown).
An archive of randomly mutagenised Cre libraries present in our lab was subsequently
cloned into the pEVO-loxltr to produce pEVO-loxltr-lib and analysed for recombination
in the same manner as for Cre. The starting mutant Cre library was unable to recognise
the loxltr target and the expected PCR product was not obtained even at the high level of
arabinose induction (data not shown). This result reflected that the asymmetry and the
mutations in loxltr were not recognizable by the mutant Cre library to have any residual
recombinational activity and it was not possible to begin directed evolution process.
5.4 Splitting up of loxltr into pallindromic subsets.
The rationale therefore was to split the original loxltr target into subsets which are
pallindromic to facilitate the evolution process. Two additional pallindromic target sites,
loxltr1 and loxltr2 were created based on the original aymmetric loxltr sequence, with the
LE and RE sequences respectively used to form an inverted repeat sequence as is in loxP
(fig.10).
The loxltrs 1 and 2 were cloned into the evolution vector to give pEVO-loxltr1and
pEVO-loxltr2. Recombination at these new pallindromic targets were tested by
subsequent cloning of Cre recombinase into the evolution vectors, pEVO-loxltr1 and
pEVOloxltr2. As before recombinase expression was induced with 200µg/ml of L-
arabinose but none of these two subsets were recombined by the Cre (data not shown).
When the mutagenised Cre library was cloned into these vectors, and induced with
arabinose, the same result was repeated and no recombination was observed (data not
shown).
This led to the conclusion that the pallindromic nature of the sub-sets was not enough and
that the mutations in these sites were still too many for the starting library to have any
action, and this necessitated the further splitting of loxltrs1 and 2 by evenly dividing the
half-site mutations in the left element (LE) and right element (RE). The mutations of the
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half-sites of loxltr1 and 2 were thus split equally to form four new subsets, loxltrs1a, 1b,
2a and 2b. The sequences of all the loxltr subsets are shown in Fig.10.
Fig.10.  Splitting scheme of loxltr site.  Left 13 bp and right 13 bp sequences of loxltr has been
respectively used to form pallindromic 34 bp sub-sets loxltr1 and loxltr2. Both these target sites have the
original spacer of loxltr. The loxltr1 half-sites are in red with the mutated residues with respect to loxP in
bold, and the loxltr2 half-sites are similarly represented in green. The loxltrs1a and 1b are derived from
loxltr1 and have two half-site mutations each shown in red, whereas loxltrs2a and 2b have three half-site
mutations each shown in green and are split sub-sets of loxltr2. Arrows depict the manner in which the sub-
sets originated from loxltr.
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5.5 Directing evolution of recombinases for loxltrs 1a, 1b, 2a and 2b.
The four new loxltr sub-sets 1a, 1b, 2a and 2b were cloned in the pEVO vector. Cre
recombined only loxltr1a at an arabinose induction of 200µg/ml, and the expected PCR
product of 1.7Kb was produced, but the other three loxltr subsets were not recombined by
wt Cre (data notshown).
Expression of the mutagenised library (lib1) with the same arabinose induction
(200µg/ml) resulted in recombination at sites 1a, 1b, 2a and 2b (Fig.11). Plasmid DNA
was isolated from the overnight cultures of evolution vectors, pEVO-loxltr1a-lib1,
pEVOloxltr1b-lib1, pEVO-loxltr2a-lib1 and pEVO-loxltr2b-lib1, and digested with Nde1
followed by PCR (Fig.11a) and also with BsrG1-Xba1 to analyse for recombination at the
respective targets (Fig.11b).
(a).                                                           (b).
Fig.11. Activity of mutagenised Cre library on different loxltr subsets in the first evolution cycle.
(a). PCR product of 1.7 Kb reflecting recombination after Nde1 digest of the evolution vectors pEVO-
loxltr1a-lib1, pEVOloxltr1b-lib1, pEVO-loxltr2a-lib1 and pEVO-loxltr2b-lib1.
(b). BsrG1-Xba1 of plasmid DNA to analyse for recombination at loxltrs 1a, 1b, 2a and 2b at the first
evolution cycle.
The lower 4.2Kb band corresponding to the recombined product was evident for loxltrs1a
and 2a from BsrG1-Xba1 digest. The 1.7Kb PCR product corresponding to each substrate
was digested with BsrG1-Xba1 and the successful recombinase libraries were sub-cloned
back into the respective evolution vectors to start the next cycle. This result showed that
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splitting the mutations facilitated recognition by the mutagenised Cre library, and hence
served as a starting point for subsequent directed evolution cycles. The aim now was to
enrich through each cycle functional recombinases recognizing these four targets and
then merging them in a combinatorial approach to carry out evolution using the next
higher sub-sets loxltrs1 and 2 as targets.
5.6 DNA shuffling and stringent selection to generate functional
recombinases.
The directed evolution strategy described here also takes into consideration two facts.
First, recombinases capable of recognising the loxltr sites were shuffled at every third
cycle of evolution. DNA shuffling is a process of randomly recombining different
sequences of functional genes in a combinatorial fashion. This method searches much
larger regions of sequence space with a bias towards functional sequences of improved
fitness. The technique of DNA shuffling used here was that of random fragmentation and
PCR reassembly (Stemmer, 1994). The recombinases in each library corresponding to
each loxltr were randomly fragmented using sonication, and these fragments were
reassembled by PCR (described in the materials and methods section) without primers
through pairing of homologous sequences. This process creates a library of chimeric
sequences containing crossovers between different parent sequences to create more
genetic diversity based on recombination. The primerless PCR product is then used as a
template for a regular PCR using defined primers flanking the recombinase coding region
to amplify the reassembled strands to give a full-length product. The outcome of a typical
shuffling reaction is shown in Fig.12.
The final 1Kb PCR product corresponding to the shuffled recombinase libraries were
digested with BsrG1-Xba1 and sub-cloned back into the evolution vectors. We used a
molecular breeding protocol where every third cycle of evolution was shuffled. DNA
shuffling typically results in a reduced fitness in the library in the F1 generation,
however, with the subsequent screening and selection there is rapid improvement in the
F2 and later generations as a result of a combination of different mutations in the shuffled
libraries (Fig.13).
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Fig.12. DNA shuffling. (a) Son.Lib.S1 and Son.Lib.S2 correspond to two sonicated recombinase libraries.
Lib.S1 First PCR and Lib.S2 First PCR are the products of the primerless PCR, typically the smear moves
up as recombinase coding regions are amplified depending on homology.
(c) PCR amplification using defined primers flanking the recombinase coding region produces a 1Kb band
as shown. The lower band corresponds to a background band resulting from amplification of vector
sequences without recombinase. L= 1Kb ladder.
Fig.13. Bsrg1/Xba1 digestion of pEVO-loxltr1a libraries for first 9 cycles of evolution. Note that the
cycles 3, 6 and 9 (shuffled cycles) display a reduced recombination efficiency reflected by the intensity of
the lower 4.2Kb band, which rapidly improves in the subsequent cycles. The arabinose inductions for the
recombinase libraries are listed in Table1.
 Apart from shuffling, the stringency of selection was increased by concomitantly
reducing the L-arabinose concentration used to induce expression of recombinases. For
all the loxltr targets the recombinases were expressed with 200µg/ml L-arabinose in the
first cycle. The next cycles had reduced induction levels to select out more functional
recombinases and in this way the concentration of the inducer was made lower in the
506bp
220bp
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following cycles till a minimal induction resulted in recombination. The arabinose
induction used in each evolution cycle for all the loxltr subsets are shown in table1.
Another very important aspect of the evolution cycles was the library size. Throughout
the evolution process, the library size was maintained at 10,000 clones or above. In case
of decreased library size the cycles were repeated till a satisfactory colony number was
reached.
Table1. L-arabinose concentration (µg/ml) used for inducing recombinase expression for each evolution
cycle corresponding to all the loxltr sub-sets and target loxltr.
Evolution
Cycle
number
L-Ara
(µg/ml)
for
loxltr1a
L-Ara
(µg/ml)
for
loxltr1b
L-Ara
(µg/ml)
for
loxltr2a
L-Ara
(µg/ml)
for
loxltr2b
L-Ara
(µg/ml)
for
loxltr1
L-Ara
(µg/ml)
for
loxltr2
L-Ara
(µg/ml)
for loxltr
1 200 200 200 200 200 200 200
2 200 200 200 200 200 200 200
3 200 200 200 200 200 200 200
4 200 200 200 200 200 200 200
5 200 200 200 200 200 200 150
6 200 200 200 200 200 200 150
7 75 75 100 200 100 100 125
8 10 50 50 100 100 100 100
9 10 10 10 50 100 100 50
10 10 10 10 50 75 75 50
11  0 0 0 10 50 50 50
12  0 0 0 5 10 10 50
13  0 0 0 5 10 10 30
14  0 0 0 2 10 10 30
15  0 0 0 0 10 10 30
16 0 5 5 30
17 0 30
18 0 25
19 25
20 15
21 15
22 15
23 10
24 5
25 5
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5.7 Enrichment in libraries with efficient recombinase clones through cycles
of evolution at different loxltrs.
The number of evolution cycles required to obtain highly efficient recombinases for each
loxltr is not pre-determinable and varied with the evolvability of the starting mutagenised
recombinase library with respect to the loxltr targets. The final aim was to have good
library size and quality at minimum induction.
Among all the four starting loxltr targets, recombinases recombining loxltr2b was
relatively difficult to evolve, compared to the other three. By cycle 9 the L-Ara
concentration to induce recombinase expression was decreased to 10µg/ml for loxltrs 1a,
1b, and 2a and 50µg/ml for loxltr2b. Functional libraries were obtained even in absence
of induction by cycle 10 for loxltrs1a, 1b, and 2a and by cycle 15 for loxltr2b. Successive
cycles of evolution, shuffling, screening and selection led to an increase in recombination
at the different loxltr subsets. Restriction analysis of recombinase libraries using
Bsrg1/Xba1 digestion, at cycle 1 and cycle 10 are compared for loxltrs1a to 2b (Fig.14a).
The tenth libraries for all the four target sites had distinct improvement in recombination
efficiency compared to the first cycle. The evolution process was carried out for 15 cycles
for loxltrs1a, 1b, and 2a and a total of 19 cycles were performed for loxltr2b. The
evolution cycles were stopped when a satisfactory library quality was obtained at
minimum possible induction.
5.8 Sequence analysis of evolved recombinases for loxltrs 1a, 1b, 2a and 2b.
Individual recombinases were sequenced to determine amino acid changes resulting in
altered specificity. The comparative analyses of several recombinases with the same
specificity would allow the identification of important residues which confer the change
in specificity. Individual recombinases clones were randomly picked from evolution
cycles 8, 9 and 10 for all the four loxltr subsets and analysed functionally using
Bsrg1/Xba1 digestion and through sequence analysis.
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Fig.14. Restriction analysis of recombination mediated by loxltr subset libraries and individual
clones. (a). Bsrg1/Xba1 digestion of recombinase libraries for loxltrs1a, 1b, 2a and 2b at cycle 1 and cycle
10 of evolution. The recombinase libraries are induced with 200µg/ml arabinose at cycle1 for loxltr1a, 1b,
2a and 2b and at cycle10 with 10µg/ml for loxltrs 1a, 1b, and 2a and 50µg/ml for loxltr2b. Improvement in
recombination efficiency is evident at cycle 10 for all the loxltr subsets.
(b) to (e). Bsrg1/Xba1 digestion of some selected recombinase clones for loxltrs 1a, 1b, 2a and 2b, the
respective cycle numbers and L-Ara induction concentrations are shown.
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Table2. Amino acid mutations in some selected recombinases for loxltrs 1a to 2b. The residues in red
are known to contact DNA from the wt Cre crystal structure. The hyprevariable residues are in bold for
both contact and non-contact sites.
Evolved
recombinases for
loxltr1a, 1b, 2a and
2b.
                         Amino acid mutations.
1a.9.1(5µg/ml ara) K25E, D29G, A127V, E138G, M149I, D341N
1a.9.2(5µg/ml ara) M28A, M97I, V125I, I166T, G229D, D232V
1a.10.1(0µg/ml ara) G82S, E150A, L171V, V204A, I320M
1a.11.2(0µg/ml ara) A175G
1a.11.3(0µg/ml ara) N3D, V7L, K62R, M97L, E138G, D329A
1a.11.7(0µg/ml ara) D29A, V145I, E262Q, S305P, T316A
1b.8.1(50µg/ml ara) N59T, I88V, I166V, I174M, S186T, S214I, P234L, V242A, E262A
1b.8.2(50µg/ml ara) V7L, K62N, A112V, R146C, L161Q, F163L, G208R, R241P, E262G, D341G
1b.9.1(10µg/ml ara) V7L, Q94L, S108G, E123K, N151T, T268A, N317T, I320M
1b.9.2(10µg/ml ara) V7L, C155R, E262Q, N317T, I320S
1b.10.1(0µg/ml ara) N3D, V7L, S108C, D143N, E262Q, N317T, I320S
1b.10.2(0µg/ml ara) N3D, V7L, S114P, D189G, E262G, I306T
2a.9.1(10µg/ml ara) L5P, L14F, Q156R, D189G, M193A, L215Q, I320S
2a.9.2(10µg/ml ara) G93A, A112T, E138G, D143G, D278G, T316A
2a.10.1(0µg/ml ara) V7L, Q94L, R118G, A127P, D153N, A178P, N319S
2a.10.2(0µg/ml ara) N10H, P107I, T253S, T316A, I320S
2a.10.3(0µg/ml ara) T6S, D21E, Q94L, L98I, E138G, G198S, A231V
2a.10.5(0µg/ml ara) T19M, Q35R, E150V, G191E, G198S, S254C, D278G
2b.9.1(50µg/ml ara) V7L, V16A, M30V, Q35P, N59S, A131V, D157E, A249T, R259C, E262Q, N317T,
I320S, T332A
2b.9.2(50µg/ml ara) V7L, R24H, M28I, A36V, F37L, D73Y, Y77H, P107L, A131V, T206A, E262A,
D277G, N317T, I320S
2b.9.3(50µg/ml ara) V7L, V16A, M30V, Q35P, S108G, G208R, E262A, N317T, I320S, G342W
2b.10.1(10µg/ml ara) V7L, V16A, M30V, V71A, N111S, Q156K, A249T, Q255R, R259C, E262Q, N317T,
I320S
2b.10.2(10µg/ml ara) N3D, V7L, M30V, Q35P, S108G, A249T, E262Q, A267G, N317T, I320S
2b.10.3(10µg/ml ara) V7L, V16A, M30V, Q35P, Y77H, G93C, Q156K, R259C, E262Q, N317T, I320S
At least 10 different clones of evolved recombinases for the four loxltr subsets were
sequenced and functionally analysed by restriction digestion, the recombination
competence at respective target site (Fig. 14b-14e) and the corresponding amino acid
changes in the six best recombinases per loxltr subset are shown in Table2.
The average number of amino acid mutations for recombinases recognising loxltrs1a, 1b,
2a ranged from 6 –10 per clone though interestingly the clone 1a.11.2 had just one
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mutation suggesting that one single mutation can be sufficient to allow better
recombination at loxltr1a (Table2). Most of the mutations were at non-contact sites, and
the mutations were not hypervariable especially for the sequenced clones of recombinases
for loxltrs1a and 2a, hence it was not possible to assign a particular mutation to a
particular loxltr.  But there were some interesting mutations, which are M97L or M97I
for loxltr1a recombinases, S108G/C and E262G/A/Q for loxltr1b recombinases and
G198S for loxltr2a recombinases. The mutations have been mapped onto the wt Cre
secondary structure to get an idea of their distribution (fig.15). In case of individual
sequenced recombinase clones for loxltr2b, 70% of the sequences had Arg259 mutated to
Cys, and all the clones contained Glu262 mutation to Gln or Ala. This is interesting
because both the positions 259 and 262 make sequence specific contact with the lox site
around base pairs 5-7 in the half-sites. Interestingly all the clones for loxltr2a had N317T
and I320S mutations. These residues surround the helix M and have been previously
implicated in broadening or shifting of mutant Cre specificity (Hartung and Kisters-
Woike 1998). (The mutations will be discussed in greater detail in the Discussion
section).
                                                                                                                                    Results
51
Fig.15. Mapping of mutations onto Cre secondary structure. The colour code of the mutations for the
respective recombinases are shown in the figure. Amino acid mutations appearing more than once add to
the bar. The secondary structural elements of Cre are shown as bars for α-helices (AtoN) and arrows for β-
sheets (1to5). The catalytic tyrosine is denoted by “Y”.
5.9 Generation of loxltr specific recombinases using combinatorial SliDE.
Once libraries of functional recombinases were generated which recombined these four
subsets, the libraries recombining loxltrs 1a and 1b and loxltrs 2a and 2b were pooled and
shuffled and the next phase of evolution was started to achieve recombination at loxltr1
and loxltr2 respectively. The reason of this combinatorial approach was due to the fact
that the half-site mutations in loxltr1 and loxltr2 targets were additively present in the
half-sites of loxltrs1a and 1b, and loxltrs2a and 2b, respectively. DNA shuffling of
recombinase libraries was performed to recombine and unify those mutations in the
recombinases which are responsible for conferring specificity to the lower sub-sets
loxltr1a, 1b, 2a and 2b. The evolution protocol was the same as before. The first cycle
with the shuffled libraries were induced with 200µg/ml arabinose. The expected PCR
product after Nde1 digest, corresponding to recombination was obtained for both loxltr1
and loxltr2 when shuffled recombinase libraries for loxltrs (1a and 1b) and (2a and 2b)
respectively were used. However no recombination was obtained when the randomly
mutagenised Cre library (starting library) was used, which reflects that combining
recombinase libraries which separately recognize and recombine the mutations in the split
loxltr subsets, can be used to achieve recombination at loxltrs 1and 2, and thus we started
evolving functional recombinase libraries for loxltrs 1and 2. The synergistic effect of the
shuffled libraries of the lower subsets led to the generation of recombinases which
recombined loxltrs1 and 2.  The improvement in library quality was very slow for both
loxltrs1 and 2, especially for the former. This could be attributed to the increased
complexity in these targets compared to the former split targets. The libraries were
induced with 200µg/ml arabinose till cycle11 for loxltr1 and cycle9 for loxltr2 to stabilize
the pool of positive candidates in the recombinase libraries (Table1). A total of 20
                                                                                                                                    Results
52
evolution cycles were carried out for loxltr1 and 17 cycles for loxltr2 at a minimum
possible induction of 5µg/ml arabinose.
Two recombinase clones, 1.17.4 (corresponding to a loxltr1 specific recombinase clone 4
of library17) and 2.12.14 (corresponding to loxltr2 specific recombinase clone 14 from
library12) which displayed 50% recombination activity on their respective substrates
were analysed for cross recombination activity and also for their activity on the native
loxP target under induced (50µg/ml arabinose) and uninduced conditions (Fig.16). Both
the recombinases retained recombinational activity on loxP even in absence of induction
and displayed over 50% recombination at loxP under induction, but interestingly showed
no cross recombination, that is 1.17.4 did not recombine loxltr2 and 2.12.14 did not
recombine loxltr1. Thus the recombinases retained their recombination potential at loxP
the native substrate, but did not have completely relaxed specificity as they did not show
cross-recombination. This reflects that through the course of directed evolution, the
recombinases acquire novel specificity but retain memory of their original targets, but
they are not necessarily absolutely substrate ambiguous.
Fig.16. Restriction analysis of recombination mediated by loxltr1 specific recombinase, 1.17.4 on loxP
and loxltr2, and loxltr2 specific recombinase, 2.12.14, on loxP and loxltr1.
The respective lanes have been labeled. The lower band represents the recombined band.
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5.10. Sequence analysis of evolved recombinases for loxltr1 and loxltr2.
Individual recombinases were randomly picked from library17 for loxltr1 and library12
for loxltr2 for functional and sequence analysis. A total of 24 individual recombinase
clones for loxltr1 and 20 individual clones for loxltr2 were analysed for recombination
efficiency by BsrG1-Xba1 digestion. All the recombinases were induced with10µg/ml
arabinose. Among the clones analysed for recombination at loxltr1, 14 showed above
50% recombination at the target site, and 17 recombinases displayed 50-60%
recombination efficiency at loxltr2 (data not shown). All the sequenced recombinases had
different sequences and no sequence was repeated reflecting that the evolution process
was not complete and more variants were still being generated. Ten best clones were
selected for sequence analysis for loxltr1 and loxltr2. Amino acid mutations of
recombinases sequenced have been listed in Table3.
The number of amino acid mutations increased with the complexity of the target loxltr,
and the average number of mutations in recombinases for loxltrs1 and 2 were between 10
to13. The sequenced loxltr1 recombinases had the glutamate262 mutated to either
Gly/Arg/His/Ala. The other most prominent mutations were at positions 94, 108, 317 and
320.
All the loxltr2 recombinases had a chain of mutations appearing persistently N245Y,
R259Y, E262Q, G263R of which the first three amino acids make contacts with the lox
site in the wt Cre-loxP complex. The implications of these mutations will be discussed in
greater detail in the Discussion section.
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Table3.  Amino acid mutations for some selected clones for loxltrs 1and 2. The recombinases were
induced with 10µg/ml arabinose and dispayed between 50 to 60% recombination at their respective target
sites. The residues in red are known to contact DNA from the wt Cre crystal structure. The hyprevariable
residues are in bold for both contact and non-contact sites.
Evolved
recombinases
for
loxltr1  and
loxltr2.
                                           Amino acid mutations.
1.16.3 L75F, V85A, Q94L, S108G, C155R, G198S, E262G, D278G, N317H, I320S
1.16.4 V85A, Q94L, S108G, G198S, D232E, E262G
1.16.11 V48I, R50Q, Q94L, V230A, S257T, E262R, N317T, I320S
1.16.14 V23A, L75F, V85A, Q94L, R101Q, S108G, G230A, E262H, N317T, I320S.
1.16.16 V7L, Q9H, N10S, V23A, D29E, R34H, K62E, L75F, V85A, Q94L, S108G, L164P,
T206A, F239L, V247A, E262H, N317T, I320S
1.16.18 V85A, Q94L, S108G, D153N, G198S, D232E, E262G, N317T, I320S
1.17.2 V85A, Q94L, S108G, I174M, T206A, F239L, E262A, D278G, N317T, I320S
1.17.4 L75F, V85A, Q94L, S108G, G198S, E262R, D278G, N317T, I320S
2.12.1 T61, V7L, V16A, R24C, M30V, K57E, G93C, Q156K, I166V, N245Y, R259Y, E262Q, G263R,
 I272V, N317T, I320S
2.12.3 M44T, S51L, Y77H, G93C, P107L, N245Y, R259Y, E262Q, G263R.
2.12.13 N3D, V7L, V16A, Q35P, K57E, Y77H, G93C, P107L, A131V, S147L, Q156K, N245Y, R259Y,
 E262Q, G263R, N317T, I320S
2.12.14 V7L, V16A, V23A, M30V, Y77H, G93C, P107L, Q156K, R243G, N245Y, R259Y, E262Q,
G263R.
2.12.16 V7L, G93C, Q156K, A175G, E222G, N245Y, R259Y, E262Q, G263R, N317T, I320S
2.12.18 Q35P, Y77H, G93C, Q156K, N245Y, R259Y, E262Q, G263R, N317T, I320S
2.12.9 M28I, M30V, Q35P, Y77H, G93C, A131V, N245Y, R259Y, E262Q, G263R
K57E, G93C, N245Y, R259Y, E262Q, G263R, N317T, I320S
4.11 Tre recombinases.
The same combinatorial approach was followed up to achieve specificity for the final
target loxltr from shuffled libraries of loxltr1 and loxltr2. Recombinase libraries pEVO-
loxltr1-lib17 and pEVO-loxltr2-lib15 were mixed in equal proportions, shuffled and
evolution was started with this library. The shuffled library was cloned into the pEVO-
loxltr vector and recombinases induced with 200µg/ml of L-arabinose. The plasmid DNA
from the overnight culture was digested with Nde1 and PCR was performed. The
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expected 1.7 Kb band was obtained, which once again proved that combining two
recombinase libraries (for loxltr1 and loxltr2) which separately recognize the mutations in
the right and left arms in the final target did work to achieve recombination at loxltr. The
PCR product was sub-cloned back into the loxltr evolution vector and the final stage
evolution was started to achieve specificity at loxltr. The arabinose concentration used to
induce recombinase expression at each cycle is shown in table1. A total of 25 cycles of
evolution were performed for the final loxltr substrate till considerable recombination
was obtained under low induction with 5µg/ml arabinose. The battery of recombinases
recombining loxltr were termed Tre recombinases (for recognizing and recombining a
sequence from a long ‘terminal repeat’).
The summary of this very extensive evolution process have been presented in Fig.17. The
most noteworthy and novel feature of this strategy was that, it was possible to generate
functional recombinases that recognize the asymmetric loxltr by combining recombinases
which separately recognize the loxltr subsets with different mutations all present in the
final substrate.  Such a combinatorial approach can thus be applied to generate
recombinases for highly variant asymmetric sites compared to the native or original
target. A total of 126 evolution cycles were performed through all the subsets to achieve
recombination at the final target loxltr.
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loxltr
loxltr1
loxltr2
loxltr1a
loxltr1b
loxltr2a
loxltr2b
Combine and shuffle
25 cycles
17 cycles
20 cycles
15 cycles
15 cycles
19 cycles
15 cycles
Analysis of
individual clones
and selection of 
final recombinase.
Fig.17. Summary of the directed evolution process. The number of evolution cycles performed for each
loxltr subset is shown besides the respective targets, and the merging of specific subset libraries are shown
with arrows.
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5.12 Selection of final Tre recombinase.
Evolution of loxltr specific recombinases was halted after the 25th cycle at an induction of
5µg/ml arabinose. Fifty individual recombinases were randomly picked, induced with
5µg/ml arabinose and functionally analysed using Bsrg1/Xba1 digestion. Among the
clones analysed, 17 clones displayed 40-50% recombination at loxltr at the induction
used, the other clones showed less and were excluded. Bsrg1/Xba1 digestion of 10
recombinases from the 17 that had satisfactory recombination at loxltr is shown in
Fig.18a. These clones were sequenced for mutation analysis and amino acid mutations of
eight of the best sequenced recombinases is shown in Table 4. Again as for all other
sequenced recombinases none of the sequences of the Tre recombinases were repeated
reflecting the presence of diverse clones in the evolved library and also that the evolution
process was not yet completed.
The best clone (clone 42, Fig.18a) screened from the 25th cycle, that recombined loxltr to
50% was selected for further analysis in E.coli and mammalian cells. The chosen
recombinase has been termed as Tre25.
Tre25 was cloned into pEVO-loxP to produce pEVO-loxP-Tre. The specificity of Tre25
for the target loxltr and the native loxP was compared by transforming the two vectors,
pEVO-loxP-Tre and pEVO-loxltr-Tre into E.coli DH5α , and then inducing the
recombinase at different arabinose concentrations ranging from zero to 100µg/ml.
Tre25 recombined loxltr to a maximum extent of 80%, whereas at the same induction
Tre25 recombined loxP to a maximum extent of 50% (Fig.18b and c). No recombination
was observed at either substrate in absence of induction and no improvement in
recombination efficiency was observed beyond 50µg/ml arabinose induction. Thus Tre25
retained some specificity at loxP though the efficiency of recombination was higher for
loxltr.
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Fig.18.  Screening of Tre recombinases by restriction analysis and recombination specificity of
selected Tre25 at loxltr and loxP.  (a). Bsrg1/Xba1 digestion of 10 different clones at 5µg/ml arabinose
induction from the loxltr library after 25 evolution cycles. The clone 42 (termed as Tre25) marked in red
was selected for further analysis.
(b) Recombination at loxltr target mediated by Tre25 (labeled as ‘Tre’ in the lanes) at different arabinose
inductions. The inductions used are shown in the figure.
(c) Recombination at loxP target mediated by Tre25 (labeled as ‘Tre’ in the lanes) at different arabinose
inductions.
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5.13 Specificity analysis of Tre15 and Tre25.
Laboratory evolution can provide insight into the mechanisms of adaptive molecular
evolution. Evolved enzymes tend to display broadened substrate specificity, which
suggests that enzymes fluctuate through more specific or ‘specialist’ state to a more
‘generalist’ and gradually acquire a more ‘specialist’ state during evolution ((Matsumura
and Ellington 2001). To test whether this trend can be seen in our in vitro evolution, we
analysed the specificity of a recombinase from an earlier evolution cycle (cycle15) with
the final selected Tre25 from cycle 25.
Tre15 and Tre25 were cloned into the pEVO versions of loxP and all the loxltr substrates
and analysed for recombination by restriction analysis at 50µg/ml induction.  Tre15
recombined loxltr to almost 50% whereas Tre25 recombined to almost 80%. Tre15
displayed much more relaxed specificity and recombined loxltrs1, 2, 1b, 2a, and 2b,
whereas at the same induction Tre25 recombined only loxltr2b (data not shown). Both the
variants recombined loxP with Tre15 recombining loxP a greater extent in comparison to
Tre25. This result is interesting as it shows that as evolution proceeded from cycle 15 to
cycle 25, the Tre recombinases slowly lost their specificities for most of the loxltrs,
though they retained recombination potential at loxP.
5.14 Sequence analysis of evolved Tre recombinases and identification of
mutation hotspots.
The Tre recombinases had around 15 mutations per sequenced clone. There were several
mutations which were lost during course of evolution to the higher target loxltr, and some
mutations which rose later and became fixed suggesting that epistatic interactions occur
during in vitro evolution.
The distribution of mutations of the recombinases for loxltr, loxltr1 amd loxltr2 revealed
a clustering of residues through the course of evolution. High density of hypervariable
codons were present in helix J followed by helix D (Fig.19).  The 4-5 linker and L-M
linker had clustering of mutations at positions 245 and 317 respectively. Helix J amino
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terminus interacts with the major groove where Arg259 forms hydrogen bonds with N7
and O6 of guanine 10 (Guo et al., 1997). The structural determinants of substrate
specificity are difficult to predict with sequence comparison alone, yet the mutations do
give an idea of the plasticity residues contributing to directed molecular evolution.
Three clusters of mutational hotspots are evident in case of the sequenced Tre
recombinases, the first at positions 85, 94 and 108, which were also present in 90% of the
sequenced clones of loxltr1 recombinases (Fig.19). The fact that these codons were
hypervariable in the Tre recombinases suggest that this cluster of mutations were
contributed by the loxltr1 specific recombinase library. A second cluster of hypervariable
codons were at positions 245, 259, 262 and 263. These residues were also hypervariable
in clones of loxltr2 recombinases. The codons 259 and 262 were also hypervariable in
loxltr2b recombinases and the 262 codon was also mutated in sequenced recombinases of
loxltr1b (tables2, 3 and 4). It is possible that the first and second mutation clusters are
responsible for facilitating recombination at loxltr1 and loxltr2 respectively. Shuffling of
loxltr1 and loxltr2 recombinase libraries for directing evolution of recombinases for loxltr
have combined these mutations and sequestered them in the Tre recombinases. The final
clustering are at positions 317 and 320, which were recurrently mutated in all sequenced
recombinase clones of loxltr2b, 1 and 2.
Apart from positions 259 and 262 the other residue of interest which was mutated in all
the Tre and loxltr2 recombinases was Asn 245. This residue is the last in a stretch of
amino acids which contact DNA in the wild type recombinase and was consistenly
mutated to Tyr suggesting that this mutation was important for recognition of loxltr and
also the subset loxltr2. The amino acid mutations of the selected Tre recombinase
(Tre25.42) is shown in Table 4. None of the sequenced Tre recombinases had identical
sequences, a property observed also for the other loxltr subset recombinases.
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Table4. Amino acid mutations for some selected recombinase clones for loxltr. The recombinases were
induced with 5µg/ml arabinose. The recombination proficiency of the clones can be seen from fig.12a. The
residues in red are known to contact DNA from the wt Cre crystal structure. The hyprevariable residues are
in bold for both contact and non-contact sites.
Tre
recombinases
from cycle25.
                     Amino acid mutations.
Tre25.42
(selected for cell
culture)
V7L, Q9H, N10S, V16A, M30V, Q35P, K43E, Y77H, G93C, Q94L, A131T, I166V, K244R,
N245Y, R259Y, E262Q, G263R, N317T, I320S.
Tre25.6 E22G, F37S, A84V, V85A, Q94L, S108G, K132N, I166V, A175S, N245Y, R259Y, Q281R,
N317T, I320S.
Tre25.7 L5Q, V7L, P12S, L14S, P15L, V23A, A80V, V85A, Q94L, S108G, G198S, N245Y, R259Y,
E262Q, G263R, T268A, N317T, I320S.
Tre25.27 T6I, V7L, Q9H, N10S, V23A, V85A, Q94L, K132N, I166V, A175S, D232G, N245Y, R259H,
E262Q, G263R, N317T, I320S.
Tre25.29 L59W, Y77H, V85A, Q94L, S108G, N245Y, R259Y, E262Q, G263R, N317T, I320S.
Tre25.1 V7L, Q9H, N10S, K57E, V85A, Q94L, S108G, G198S, N245Y, R259H, E262Q, G263R, Q281R,
N317T, I320S.
Tre25.10 V7L, Q9H, N10S, V23A, V85A, I88V, Q94L, S108G, M149I, I166V, N245Y, R259Y, E262Q,
G263R, N317T, I320S.
Tre25.21 V7L, Q9H, N10S, V23A, R34H, V85A, Q94L, S108G, K132N, I166V, A175S, I225V, N245Y,
R259Y, E262Q, G263R, N317T, I320S.
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Fig.19. Mapping of mutations onto Cre secondary structure. The colour code of the mutations for the
respective recombinases are shown in the figure. The positions showing hypervariability and sequestering
of mutations from recombinases of loxltr1 and 2 are marked.
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5.15 Analysis of Tre recombinase activity in mammalian cells.
Once the evolution process was stopped, the next important requirement was to
investigate whether our evolved recombinase was active in mammalian cells. In this
section and the coming sections the selected Tre25 recombinase would be referred to as
just Tre recombinase for simplicity.
To evaluate the activity of Tre in mammalian cells, a lacZ based reporter assay was used.
The reporter plasmid for analyzing recombinase activity contains a puromycin resistance
gene (pac) flanked by loxltr or loxP sites, followed by a lacZ gene, such that
recombination at target sites would turn on lacZ expression by removal of an intermediate
stop sequence and cells subsequently stained with X-gal would be blue (Fig.20). The
loxltr was cloned into this reporter vector to give psvltr, the loxP version is psvpaX.
Cre or Tre recombinase was cloned in a mammalian expression vector, containing the
human cytomegalovirus major immediate early promoter/enhancer, a synthetic intron
known to enhance the stability of the transcript, an ECMV IRES followed by an
antibiotic resistance marker. The IRES facilitated the expression of the selection marker.
The recombinases were cloned into the pIRES-Hyg version, and the vectors were re-
named as pIRES-hyg-Cre and pIRES-hyg-Tre.
                  Fig. 20. Reporter assay for evaluating recombinase activity in Hela cells.
pac
Loxltr/LoxP Loxltr/loxP
lacZ
Transfection with recombinase
 expression vector.
lacZ
Recombination  turns on lacZ expression and 
also results in loss of puromycin resistance.
SV40
SV40
X-gal
Blue cells
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a)
b)
Fig.21. Assay for transient recombinase activity in Hela cells. (a) Hela cells were co- transfected with
Cre or Tre recombinase and reporter plasmids. The cells were fixed and stained with X-gal 48 hours post
transfection. Recombination deletes a 1.1 kb stop region (denoted as ‘pac’ for puromycin acetyl transferase,
that prevents expression of lacZ. in fig.9) and results in turning on lacZ expression reflected by blue cells.
(b) Measurement of β-galactosidase activity in cell lysates of Hela cells co-transfected with recombinase
and reporter plasmids. The β-galactosidase activity is presented as a percentage of the enzyme activity of
cells after parallel transfection with the recombined forms of reporter plasmids psvΔpax and psvΔltr.
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Hela cells were co-transfected with pIreshyg versions of recombinase plasmids and
psvpax or psvltr reporter plasmids. Recombinase activity was evaluated 48 hours post
transfection using X-Gal staining and also measurement of β-galactosidase activity. X-
Gal stained blue cells are evident for Cre/psvpaX, Tre/psvltr and Tre/psvpaX
transfections, but not for Cre/psvltr (Fig.21a). The β-galactosidase activity for
transfection of Hela cells in parallel with recombined psvΔpax or psvΔltr was set to
100%. Co-transfection of pIreshyg-Cre with psvpaX generated almost 30% of β-
galactosidase activity within 48 hours post-transfection (Fig.21b). As in E. coli assays,
Cre did not recombine loxltr and Tre displayed relaxed specificity and recombined also
loxP, but the recombination activity of Tre was higher for loxltr substrate than for loxP,
as shown by the staining and measurement of β-galactosidase activity. The transient
assay shows that the evolved recombinase, Tre, mediates recombination in Hela cells at a
low but measurable activity in comparison to the wild-type Cre recombinase.
5.16 Tre mediated recombination at loxltr sites integrated in the genome.
The above results testify to the fact that Tre can mediate recombination in mammalian
cells, however the more important question is whether it can mediate recombination in
the genomic context, which is an absolute prerequisite for application of evolved
recombinases as genomic surgery tools.
The loxltr and loxP versions of the reporter vector were used to generate stable
puromycin resistant Hela cell lines to investigate whether Tre can recombine its target in
a genomic context. As for the transient assays the stable loxltr or loxP cell lines were
transfected with either Cre or Tre recombinase vectors, and transfected cells were
analysed for recombination after 48 hours. Two stable cell lines each for loxltr and loxP
were used for the assay. Initially the cell lines were transfected and stained with X-Gal to
test for recombination, but only one of the loxltr cell lines (loxltrHela1) showed blue cells
upon transfection with pIres-Hyg-Tre, whereas the loxP stable cell lines or the other
loxltr cell line did not show blue cells. The fact that there were no blue cells in these cell
lines could be due to silencing of the SV40 promoter driving the expression of the lacZ
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gene or that somehow that plasmid had integrated in a manner thst destroyed the lacZ
gene. I used PCR to detect recombination in stable cell lines. Transfection of the loxP
stable Hela cell lines with pIres-Hyg-Cre gave the expected 724 bp band for
recombination but no band was observed when loxltr stable cell lines were transfected
with Cre (Fig.22).
Transfection of the Tre recombinase expression vector resulted in recombination only at
loxltr target but, surprisingly not at loxP as detected by PCR, though the transient assays
showed Tre mediated recombination at loxP. It could be that the threshold of
recombinational activity of Tre at loxP were too low, and hence beyond detectable limits.
Fig.22. PCR detection of recombination in stable reporter cell lines. Recombination gives a 724 bp
band after PCR using primers as shown in the schematic representation.
The loxP and loxltr Hela stables were transfected with mock (pIres-Hyg vector), pIres-Hyg-Cre, and pIres-
Hyg-Tre vectors, and 48 hours post transfection genomic DNA was isolated from transfected cells and PCR
was performed.
PCR detection of recombination in stable Hela reporter cell lines showed that Tre does
recombine a loxltr target integrated into the genome.
To quantify the extent of recombination achieved in this assay we designed a probe to be
used for Southern blot analysis (Fig.23). A DIG-labelled DNA probe corresponding to
the lacZ region was generated. Genomic DNA was isolated from stable cell lines after
transfection with respective recombinase vectors and were probed after overnight
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digestion with Avr11 and Cla1. The reporter plasmids psvpaX and psvΔpax were
similarly digested and hybridised with the same probe as positive controls.
Recombination should result in a 950bp band in comparison to 2kb before recombination
(schematics in Fig.23).
(a)
Fig.23. Southern blot in stable loxltr reporter Hela cell line.
(a) Schematics of southern blot detection of recombination in Hela stable cell lines loxltrHela1.
(b) Southern analysis of the loxltr1 cell lines transfected in four consecutive rounds with Tre expression
vector as explained in text. DIG labeled DNA probe was used to hybridise digested Hela genomic DNA
transferred onto nylon membrane.
(c) PCR detection of recombination using primers P1 and P2.
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Southern hybridization of loxltr Hela1 DNA 48 hours post transfection with either mock,
Cre or Tre recombinase vectors did not show the lower band for recombination. Thus it
was decided to do four consecutive rounds of transfection of loxltr Hela cells with Tre
vector to enrich for recombined cells. The loxltr Hela cells were transfected with Tre
plasmid and 48 hours post transfection, the cells were passaged into two dishes, one for
isolation of genomic DNA, and the other batch of transfected cells were used for re-
transfecting with Tre plasmid.
After four such rounds, the genomic DNA from the four batches were analysed for
recombination using both PCR and southern hybridization. Though recombination was
detected by PCR, southern blot failed to show any recombined band reflecting that
recombination occurs, albeit at a low rate.
Tre mediates recombination in mammalian cells as shown by transient co-transfection
assay and also recombines its target integrated into the genome as shown by PCR of
reporter stable cell lines after transfection with the recombinase. The rate of
recombination mediated by Tre was low. Improved recombination efficiency in
mammalian cells was recently demonstrated for Cre recombinase by optimizing the
codon usage to human codon usage preferences (Shimshek et al. 2002).
5.17 Codon-optimisation of Tre.
To improve the activity of Tre in mammalian cells, the codon usage of the recombinase
was adapted to human codon usage preferences by introducing silent base mutations. The
altered version is termed as hTre (humanized Tre). Apart from codon-optimisation an
optimal Kozak consensus sequence was introduced for efficient translational initiation, an
SV40 T-NLS was included for N-end rule stability (Varshavsky 1997), and two
termination codons were introduced for efficient termination. Previously the cre gene was
similarly modified to be more eukaryotic like (Shimshek et al. 2002). The encoded iCre
(for improved Cre) was detected at about 1.6 fold higher concentration than conventional
Cre when expressed from an identical vector, and the efficiency of iCre at DNA
recombination was almost1.8 fold higher than conventional Cre. We hoped that the codon
optimized hTre would be more efficient than Tre.
                                                                                                                                    Results
69
      Sequence of codon-optmised altered hTre:
5.18 Transient co-transfection assay in Hela cells with optimized hTre.
The hTre expression vector was similar in design to the one used for Tre as before, only
the selection marker was neomycin. The resulting vector was termed pIres-neo-hTre.
GCTAGCGCCACC ATG GTG CCC AAG AAG AAG CGG AAG GTG TCC AAC CTG CTG ACC CTG CAC CAC AGC CTG CCC GCC CTG
CCT GCC GAC GCC ACC TCT GAC GAA GTG AGG AAG AAC CTG ATG GAC GTG TTC AGA GAC AGA CCC GCC TTC AGC GAG CAC
ACC TGG GAG ATG CTG CTG TCC GTG TGT AGA AGC TGG GCC GCC TGG TGT AAG CTG AAC AAC CGG AAG TGG TTC CCC GCC
GAG CCC GAG GAT GTG AGA GAC TAC CTG CTG CAC CTG CAG GCC AGA GGC CTG GCC GTG AAA ACC ATC CAG CAG CAC CTG
TGC CGG CTG AAC ATG CTG CAC AGG AGA AGC GGC CTG CCT AGA CCC AGC GAT AGC AAC GCC GTG TCC CTG GTG ATG AGG
CGG ATC AGG AAG GAG AAC GTG GAC GCC GGC GAG AGA ACA AAG CAG GCC CTG GCC TTC GAG AGA ACC GAC TTC GAC CAA
GTG AGG AGC CTG ATG GAG AAC AGC GAC CGG TGC CAG GAC ATC AGA AAC CTG GCC TTT CTG GGC GTG GCC TAC AAC ACC
CTG CTG AGG ATC GCC GAG ATC GCC CGG ATC AGG GTG AAG GAC ATC AGC AGA ACC GAC GGC GGC AGA ATG CTG ATC CAC
ATC GGC AGG ACC AAG ACC CTG GTG TCC ACA GCC GGC GTG GAG AAG GCC CTG AGC CTG GGC GTG ACC AAA CTG GTG GAG
CGG TGG ATC AGC GTG TCC GGC GTG GCC GAC GAC CCC AAC AAC TAC CTG TTC TGT AGA GTG AGG AGA TAT GGC GTG GCC
GCC CCC AGC GCC ACC TCC CAG CTG TCC ACC TAC GCC CTG CAG AGA ATC TTC GAG GCC ACC CAC AGA CTG ATC TAC GGC
GCC AAG GAT GAT AGC GGC CAG AGA TAC CTG GCC TGG AGC GGC CAC AGC GCC AGA GTG GGA GCC GCC AGA GAC ATG GCC
AGA GCC GGC GTG TCC ATC CCT GAG ATC ATG CAG GCC GGA GGA TGG ACC ACC GTG AAC AGC GTG ATG AAC TAC ATC CGG
AAC CTG GAT AGC GAG ACC GGC GCT ATG GTG AGA CTG CTG GAG GAC GGC GAC TGA TGA GGATCC
CGATCGCGGTGG TAC CAC GGG TTC TTC TTC GCC TTC CAC AGG TTG GAC GAC TGG GAC GTG GTG TCG GAC GGG CGG GAC
GGA CGG CTG CGG TGG AGA CTG CTT CAC TCC TTC TTG GAC TAC CTG CAC AAG TCT CTG TCT GGG CGG AAG TCG CTC GTG
TGG ACC CTC TAC GAC GAC AGG CAC ACA TCT TCG ACC CGG CGG ACC ACA TTC GAC TTG TTG GCC TTC ACC AAG GGG CGG
CTC GGG CTC CTA CAC TCT CTG ATG GAC GAC GTG GAC GTC CGG TCT CCG GAC CGG CAC TTT TGG TAG GTC GTC GTG GAC
ACG GCC GAC TTG TAC GAC GTG TCC TCT TCG CCG GAC GGA TCT GGG TCG CTA TCG TTG CGG CAC AGG GAC CAC TAC TCC
GCC TAG TCC TTC CTC TTG CAC CTG CGG CCG CTC TCT TGT TTC GTC CGG GAC CGG AAG CTC TCT TGG CTG AAG CTG GTT
CAC TCC TCG GAC TAC CTC TTG TCG CTG GCC ACG GTC CTG TAG TCT TTG GAC CGG AAA GAC CCG CAC CGG ATG TTG TGG
GAC GAC TCC TAG CGG CTC TAG CGG GCC TAG TCC CAC TTC CTG TAG TCG TCT TGG CTG CCG CCG TCT TAC GAC TAG GTG
TAG CCG TCC TGG TTC TGG GAC CAC AGG TGT CGG CCG CAC CTC TTC CGG GAC TCG GAC CCG CAC TGG TTT GAC CAC CTC
GCC ACC TAG TCG CAC AGG CCG CAC CGG CTG CTG GGG TTG TTG ATG GAC AAG ACA TCT CAC TCC TCT ATA CCG CAC CGG
CGG GGG TCG CGG TGG AGG GTC GAC AGG TGG ATG CGG GAC GTC TCT TAG AAG CTC CGG TGG GTG TCT GAC TAG ATG CCG
CGG TTC CTA CTA TCG CCG GTC TCT ATG GAC CGG ACC TCG CCG GTG TCG CGG TCT CAC CCT CGG CGG TCT CTG TAC CGG
TCT CGG CCG CAC AGG TAG GGA CTC TAG TAC GTC CGG CCT CCT ACC TGG TGG CAC TTG TCG CAC TAC TTG ATG TAG GCC
TTG GAC CTA TCG CTC TGG CCG CGA TAC CAC TCT GAC GAC CTC CTG CCG CTG ACT ACT CCTAGG
 M  V  P  K  K  K  R  K  V  S  N  L   L   T  L   H  H  S  L   P  A  L  
 P  A  D  A  T  S  D  E   V  R  K  N  L   M  D  V  F   R  D  R  P  A  F   S  E   H 
 T  W  E   M  L   L   S  V  C  R  S  W  A  A  W  C  K  L   N  N  R  K  W  F   P  A 
 E   P  E   D  V  R  D  Y  L   L   H  L   Q  A  R  G  L   A  V  K  T  I   Q  Q  H  L  
 C  R  L   N  M  L   H  R  R  S  G  L   P  R  P  S  D  S  N  A  V  S  L   V  M  R 
 R  I   R  K  E   N  V  D  A  G  E   R  T  K  Q  A  L   A  F   E   R  T  D  F   D  Q 
 V  R  S  L   M  E   N  S  D  R  C  Q  D  I   R  N  L   A  F   L   G  V  A  Y  N  T 
 L   L   R  I   A  E   I   A  R  I   R  V  K  D  I   S  R  T  D  G  G  R  M  L   I   H 
 I   G  R  T  K  T  L   V  S  T  A  G  V  E   K  A  L   S  L   G  V  T  K  L   V  E  
 R  W  I   S  V  S  G  V  A  D  D  P  N  N  Y  L   F   C  R  V  R  R  Y  G  V  A 
 A  P  S  A  T  S  Q  L   S  T  Y  A  L   Q  R  I   F   E   A  T  H  R  L   I   Y  G 
 A  K  D  D  S  G  Q  R  Y  L   A  W  S  G  H  S  A  R  V  G  A  A  R  D  M  A 
 R  A  G  V  S  I   P  E   I   M  Q  A  G  G  W  T  T  V  N  S  V  M  N  Y  I   R 
 N  L   D  S  E   T  G  A  M  V  R  L   L   E   D  G  D  •  • 
Nhe I
HaeII
NcoI NLS BspMI
BstNI BstNI
BspMI BspMI
PstI
BstXI StuI BstNI
BstNI
BstNI
AgeI BstNI BstNI
BstXI BstNI BstNI BstXI
HaeII PvuII PstI HaeII
BstNI BstNI HaeII BstXI
BstNI BsaI HaeII B amH I
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I used the lacZ based reporter assay to evaluate the activity of hTre in Hela cells in the
same way as for the unoptimised version of Tre.
The codon optimized version of Tre expression vector was cotransfected into Hela cells
separately along with either loxltr (psvltr) and loxP (psvpax) reporter vectors. As before
the recombination activity was evaluated using X-Gal staining and measurement of β-
galactosidase activity from Hela cell lysates 48 hours post-transfection.
a)
b)
Fig 24. Assay for transient hTre recombinase activity in Hela cells. (a) Hela cells were co- transfected
with hTre recombinase and loxP or loxltr reporter plasmids. The cells were fixed and stained with X-gal 48
hours post transfection.
(b). Measurement of β-galactosidase activity in cell lysates of Hela cells co-transfected with recombinase
and reporter plasmids. The β-galactosidase activity is presented as a percentage of the enzyme activity of
cells after parallel transfection with the recombined forms of reporter plasmids psvΔpax and psvΔltr.
                                                                                                                                    Results
71
The transient assay using hTre with psvpax and psvltr plasmids showed an improved
activity of hTre in mediating recombination in comparison to Tre (Fig.24). X-Gal
staining of Hela cells co-transfected with hTre and loxltr plasmids clearly showed an
increased proportion of blue cells, and also measurement of β-galactosidase activity from
the cell lysates gave almost 9 times higher value for hTre and psvltr plasmids than when
Tre was transfected with psvltr demonstrating the improved activity of hTre in Hela cells.
5.19 Activity of optimized hTre in the genomic context
The stable loxltr reporter cell line, loxltrHela1, was transfected with hTre vector, and 48
hours post-transfection the cells were fixed and stained with X-Gal. Parallel transfections
were carried out with the mock vector, pIres-neo, the Cre vector and the hTre vector, and
β-galactosidase activity in cell lysates were measured. There was a distinct increase in β-
galactosidase activity in cells transfected with hTre, in comparison to Tre, and efficient
recombination was also demonstrated by X-Gal staining (Fig.25).
These results showed that codon optimization of the evolved recombinase resulted in
improved recombination efficiency. The loxltr and loxP stable cell line were transfected
with hTre expression vector and neomycin pools were generated by selection for the
integration of the hTre vector into the genome of loxltr and loxP stable cell lines. These
cell lines were tested for recombination at loxltr and loxP. PCR results showed that the
optimized Tre did recombine loxP and loxltr (data not shown), whereas the unoptimised
version had not recombined loxP in the genomic context. Thus codon-optimisation did
increase activity of the recombinase both at loxltr and at loxP. However the Southern blot
in these stable cell lines did not work and failed to give recombined band. The reason for
failure of Southern blot could be that the threshold of recombinase activity was still too
low to be detectable by Southern. It could also be that the cell lines had multiple
integrants of the lacZ reporter construct, or that the DIG labeled probe was not the best
probe to use in this case. Hence we required another assay to detect extent of
recombination in stable cell lines with the loxltr integrated in the genome.
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a)
b)
Fig.25.  Recombination mediated by hTre in stable loxltr Hela reporter cell line. (a) The stable loxltr
cell line was transfected with hTre expression vector and cells were stained with X-gal 48 hours post-
transfection. (b). Measurement of β-galactosidase activity in cell lysates of the stable loxltr Hela cell line
after transfection with mock, Cre and hTre vectors.
5.20 Repression of Tat mediated transactivation from an HIV-1 LTR using a
model system.
To address the question whether recombination mediated by hTre can prevent Tat
transactivation from an HIV-1 LTR promoter, we used an HIV-1 LTR based reporter
system. The HIV-1 Tat protein is an essential viral regulatory factor which is involved in
the transactivation of genes involved in the HIV long terminal repeat and plays a critical
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role in viral replication. The loxltr sequence was cloned in an HIV-luciferase reporter
vector  (HIV_T2_LUC) within the HIV-1 HXB3 LTRs of the vector (Fig.26) and Tat
activation assays were performed. As a control, the vector containing just one 5’ loxltr
sequence (HIV_T1_LUC) was also used in the Tat based assay.
Fig.26. Map of HIV_T2_LUC vector. The vector has the loxltr sequence cloned within the HIV-1 HXB3
LTR. The 5’ LTR sequence is complete with the TAR region where Tat binds and transactivates firefly
luciferase expression. L1 and L2 denote the primer pair used for PCR detect for recombination.
Recombination via the loxltr sites will delete the luciferase coding region.
Tat activation of the HIV_ T2_LUC vector results in expression of firefly luciferase
driven by the LTR promoter. In absence of Tat there is very low level of luciferase
expression. When Hela cells were co-transfected with hTre vector along with the Tat
vector and HIV-T2_LUC vector, there was a three-fold decrease in luciferase activity as
shown by the luciferase readouts (Fig27a). When the same experiment was performed
with the HIV-T1_LUC vector which does not contain the second loxltr site, there was no
decrease in luciferase expression (Fig27b).
 To prove that the decrease in luciferase expression was a result of recombination and not
blocking the Tat activity or transcription from the LTR promoter by the recombinase, we
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performed PCR analysis for assaying for recombination from Hela DNA after Tat
transactivation. Hela cells were co-transfected in a parallel experiment with the Luc_T1
or the LucT2 vectors along with the Tat vector and the hTre expression vector. As
control, cells were also transfected with the luciferase vectors and Tat vector but not the
recombinase vector. DNA was isolated from Hela cells 48 hours post transfection, and
PCR was performed using primers in the upstream and downstream LTR sequences
(primers L1 and L2, Fig.26). Recombination results in a band size of 756 bp due to
removal of the luciferase coding sequence. In absence of recombination the band size is
2.7 kb. PCR of Hela DNA transfected with the HIV_T1_LUC vector containing just one
loxltr site produced only the higher band both in presence and absence of recombinase,
whereas when the HIV-T2_LUC vector was used, PCR of Hela DNA resulted both in the
upper and lower bands, in presence of hTre indicating that hTre mediated recombination
at the loxltr sites (Fig27c). Gel extraction of the PCR fragments followed by sequencing
confirmed the precise excision of the loxltr1flanked sequence when the Luc-T2 vector
was used  (data not shown).
To investigate whether recombination occurs in a more physiologically relevant context
of an LTR, Hela cells were transfected with the HIV_T2_LUC vectors to make stable cell
lines. However, it was not possible to obtain a stable cell line. Most likely the high
expression of luciferase was not tolerated by the cells. To overcome this problem another
reporter system was tested. The HIV-1 LTR vector has the same backbone, but instead of
firefly luciferase has chloramphenicol actetyl transferase (CAT) as the reporter gene
(Fig28). Tat transactivation at the LTR region leads to high expression of CAT activity
which can be measured by CAT ELISA.
                                                                                                                                    Results
75
Fig.27. Tat transactivation assay in Hela cells. (a) Hela cells were transfected with HIV-T2-luciferase
vector with the loxltr1 cloned in both the LTR regions of the vector, in presence and absence hTre. The
firefly luciferase activity was measured from the transfected cell lysate 48 hours post transfection. In
presence of hTre the firefly luciferase readout was lower.
(b) Transfection of Hela cells with the control version of the luciferase vector, HIV_T1_LUC with only one
loxltr cloned did not show a lower FF luciferase activity in presence of hTre.
( c )  PCR detection of recombination in Hela cells transiently transfected with HIV_T2_LUC or
HIV_T1_Luc in presence and absence of hTre vectors. The lower band represents the recombined fragment
after loss of the luciferase coding region. The lower band is absent in PCR from cells transfected with the
HIV_T1_LUC and hTre vectors.
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5.21 Transient Tat transactivation assay in Hela cells using the
HIV_CAT_T2.
Hela cells were transfected with the HIV-1 LTR based CAT vector along with Tat in
presence and absence of the recombinase and CAT Elisa was performed 48 hours post
transfection to get the CAT activity of the transfected cells. As with the luciferase vector,
recombination resulted in a lower readout of CAT activity (Fig.29), which was confirmed
using PCR analysis (data not shown).
Fig.28. Map of the HIV_T2_CAT vector. The vector has the loxltr sequence cloned within the HIV-1
HXB3 LTR. The 5’ LTR sequence is complete with the TAR region where Tat binds and transactivates
chloramphenicol acetyl transferase or CAT expression. L1 and L2 denote the primer pair used for PCR
detect recombination. Recombination via the loxltr sites will lead to deletion of the CAT coding region.
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Fig. 29. Transient Tat activation assay in Hela cells transfected with the HIV_T2_CAT vectors in
presence and absence of hTre.
The transient Tat transactivation assays worked well and recombination resulted in
around three fold reduction in the measured CAT activity, a result consistent with the
data from the luciferase assays.
5.22 Recombination mediated by hTre in HIV_T2_CAT stable Hela cell lines.
It was however important to determine the extent of recombination mediated by hTre at
the loxltr target stably integrated into the genome. A PCR assay was developed by using
primers L1 and L2 in the upstream and downstream LTRs of the HIV_T2-CAT vector
that would allow easy and fast estimation of the recombination efficiency. This PCR was
used to test for recombination in case of both the luciferase vectors (Fig.27c) and the
Cat elisa after Tat activation
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CAT vectors (which have identical plasmid backbones with only different reporter genes)
and gave higher and lower band reflecting unrecombined and recombined plasmids.
To obtain the recombined version of the HIV_T2_CAT vector, the plasmid was grown in
presence of Tre in E.coli DH5α (preparation of the recombined version is described in
materials and methods section). The HIVΔCAT clones were screened using PCR with
primers L1 and L2.
The HIVΔCAT vector was now used in combination with the unrecombined
HIV_T2_CAT vector in different ratios to perform PCR with primers L1 and L2 (Fig.29a
and b). Decreasing percentage of the unrecombined vector with respect to recombined
vector correlated with increasing intensity of the lower 756 bp band for recombination
and decreasing intensity of the higher band of 2.7 Kb. The respective band intensities of
the upper and lower band for each combination of HIVΔCAT/HIV_T2_CAT was
quantified using Image Gauge analysis and the ratio of band intensities with respect to
percentage of recombined CAT vector was used to make a standard curve. The transient
co-transfection assays with the HIV-1 LTR reporter vectors resulted in a higher
recombination rate of around 40-50% (Fig.27c) as can be estimated from the intensity of
the lower band.
To quantify the extent of recombination mediated at the loxltr target stably integrated into
the genome using PCR analysis, the HIV_T2_CAT vector was transfected into Hela cells
and selected with neomycin. Three different stable CAT Hela cell lines were transfected
with hTre expression vector or mock vector and genomic DNA was harvested 48 hours
post-transfection and analysed by PCR using primers L1 and L2. The stable cell line 7
responded best to the PCR analysis (Fig.29c). The PCR data was quantified using Image
Gauge analysis and it was found that the extent of recombination mediated by hTre was
to the extent of 9.5% in the Cat stable Hela cell line7 (Fig.29c). The CAT stable cell lines
resemble an integrated proviral construct with a full length HIV-1 LTR flanking the
reporter gene. In this experimental setup hTre recombined to an extent of around 10%
after a single round of transfection.
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(a).
(b).
(c).
Fig.29.(a). HIV_T2_CAT and HIVΔCAT vectors were combined in different ratios and PCR was
performed using the L1 and L2 primers. The intensity of the lower 756 bp band increases with the
increasing percentage of HIVΔCAT plasmid (shown on the gel) compared to the unrecombined
counterpart.
(b). The PCR results were quantified using Image Gauge analysis and the data was used to get the trendline.
(c) PCR analysis of recombination in HIV_T2_CAT stable cell lines. Out of the three cell lines, cell lines 5
and 7 were positive for the integrated construct and also for recombination.
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6. Discussion
6.1 Exploring evolvability of Cre recombinase.
Evolvability can be linked to the ability to innovate. Proteins have multiple and
unforeseeable biochemical activities or biological functions. Numerous terms are used to
describe the ability of a single protein to exhibit more than one specificity. Cross-
reactivity refers to the activities of a single protein that overlap with the original activity,
for instance, with substrates that resemble the original target of the protein.
Directed evolution of Cre recombinase and other recombinases like Flp to generate novel
variants with new substrate-specificity, have proven that these proteins are amenable to
changes. The Tre recombinases have been generated using an extensive and
combinatorial PCR based laboratory evolution strategy traversing six loxltr subsets. Each
sub-set was a different target, and it was possible to generate functional recombinases for
each of these targets. The idea was to build recombinase libraries for each pallindromic
subset with their distinct set of mutations, and recombine them by DNA shuffling to
assimilate the beneficial mutations conferring the change in specificity for each subset.
The final loxltr specific Tre recombinases were generated by combining two libraries for
loxltr1 and loxltr2, which separately recognized and recombined the pallindromic
variants derived from loxltr left and right arms. The process facilitated the generation of a
single recombinase which is able to recombine the asymmetric loxltr substrate in vivo in
E. coli and also in mammalian cells. This is the first example of tailoring Cre to
recombine an asymmetric target on an HIV-1 LTR using directed evolution and
bypassing the requirement for rational design.
Recently it has been shown that asymmetric and chimeric lox sites generated by
combining the half-sites of loxP and a variant, the loxM7 were recombined in an in vitro
recombination assay by using an equimolar mixture of wtCre and a Cre variant, CM2
(Saraf-Levy et al. 2006). CM2 was generated using both positive selection for
recombination of loxM7 and negative selection against recombination at loxP site. The
other variant CM1 used in this study was generated only using positive selection and
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displayed relaxed specificity for both loxM7 and loxP, whereas CM2 had almost 40-fold
higher efficiency for recombination at loxM7 than at loxP (Santoro and Schultz 2002).
Crystal structure analysis of these two variants have revealed the importance of solvent
network and water molecule bridging in mediating the specificity of these two
recombinase (Baldwin et al. 2003). CM1 was also found to be efficient in mediating
recombination at the chimeric asymmetric substrates. Cre or CM2 alone were not able to
recombine the asymmetric targets.
Despite the availability of structural information about Cre recombinase, and other site-
specific recombinases, it must be stated that de novo design of such a loxltr specific
recombinase would be quite difficult based on rational design approaches alone, as the
sequence space of a 343 amino acid protein like Cre would be enormous (20343).
However the information available from the laboratory evolved Cre variants, X-ray
crystal structures and mutagenesis studies made on Cre to identify the connectivities in
structure and function can lead to a point where slowly rational design and directed
evolution can be combined to generate a recombinase variant desired.
6.2. Comparative analysis of mutations in evolved Cre recombinase variants
and their target sites.
Structural, biochemical and directed evolution information of Cre variants can be
explored to identify the residues important for functional plasticity. The plasticity
residues are those that primarily govern substrate specificity and are considered
separately from the residues important for catalytic activity. Structural analysis, random
mutagenesis and phylogenetic analysis have been used to predict whether a residue is a
plasticity residue or not (Matsumura and Ellington 2001; Aharoni et al. 2004; Aharoni et
al. 2005; Yoshikuni, Ferrin, and Keasling 2006).
Since the first published crystal structure data of Cre-loxA synapse (Guo, Gopaul, and
van Duyne 1997), a lot of information is now available regarding the structural details
and the interactions of the recombinase with the target lox site (Van Duyne 2001; Martin
et al. 2002; Ennifar et al. 2003). Cre has two distinct domains, the amino terminal domain
from amino acid residues 20 to 129, and the larger carboxy terminal domain from residue
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132 to 341, separated by a short linker. The N-terminal domain consists of five α-helical
segments (A to E), among which the DNA is contacted primarily via the B and D helices.
The carboxy terminal domain of Cre consists of a nine-helix domain (helices F-N) packed
against a small β-sheet (strands 1to 3). The primarily helical C-terminal domain interacts
with the entire 13 base- pair inverted repeat region and the first two bases of the strand
exchange or spacer region. To analyse the target recognition specificity of Cre, mutants
of Cre with amino acid substitutions in the presumptive DNA binding region in the C-
terminal domain were constructed and analysed for their binding to loxP using gel
retardation assay (Hartung and Kisters-Woike 1998). The same study revealed that
binding of wt Cre was sensitive to mutations in positions 2 and 6 of the inverted repeats
of loxP. Band shift assays using symmetrical loxP sites and also symmetrical single base
substitutions in positions 2 or 6 of the inverted repeats using Cre mutants revealed that
there was broadening of specificity in case of mutants with substitutions in the region
surrounding helix M (positions 317-323) and was best illustrated by CreN317A,
CreN319C or CreN319P mutants and they could bind both loxP2 and loxP6 variants
along with loxP (Hartung and Kisters-Woike 1998).
Interestingly the sequenced recombinases for loxltr2b, loxltr1, loxltr2 and final target
loxltr consistently contained the mutations N317T and I320S (tables 2, 3 and 4).
Mutations at positions 317 and 320 were also present in seven of the published sequences
of Fre recombinases (Buchholz and Stewart 2001). These residues have been implicated
in positioning of the loxP spacer sequence for cleavage in the precleaved complex (Guo,
Gopaul, and Van Duyne 1999). The presence of the mutations at these positions in
recombinases for different target sites suggest that amino acid changes that get fixed in a
population or that were identified in independent screens likely represent residues that
might indeed be functional in broadening specificity.
Analysis of the Cre crystal structure showed that the base pairs 5 to 7 in inverted repeats
of loxP are proximal to residues 258 to 266 in helix J. The central guanine in position 6 of
loxP is recognized by Arg 259 in the major groove, where it forms hydrogen bonds to the
N7 and O6 of guanine 6. The complementary C nucleotide to this G6 nucleotide is linked
by hydrogen bonding and solvent network by Thr258, this network also includes the
Glu262 carboxylate group (Martin et al. 2002).
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The asymmetric loxltr target has a different distribution of mutations in its right arm and
left arm. The G’6 is a C in the right arm of loxltr, and also in loxltr2b, and loxltr2 subsets,
derived from the right 13 base pairs sequence, and the G5 is a C5 in the left arm, and also
in loxltr1b and loxltr2 derived from the left 13 base pairs (Fig.7 and Fig.10). All the
sequenced loxltr2 recombinases and 90% of sequenced loxltr recombinases showed
consistently the mutation R259Y. R259C was present in around 40% of the sequenced
recombinases for loxltr2b and R259H in 10% of loxltr recombinases. However among the
recombinases sequenced for loxltr1a, loxltr1b and loxltr1 the Arg259 was unchanged.
Mutation at position 259 were also present in sequences of evolved Cre recombinase
variants which recognized loxM7 target in which the residues 5,6 and 7 in the loxP
inverted repeats were mutated (Santoro and Schultz 2002). In this case two recombinases
one with relaxed specificity for loxM7 and loxP, and the other with around 40-fold higher
activity for loxM7, displayed a R259S mutation. The noticeable feature is the change
from basic Arg to a polar residue (Tyr, Ser and Cys). It could be possible that changes in
these amino acids from a basic to a polar nature somehow modify the surrounding
hydrogen bonding and solvent network to facilitate binding and recognition of the
mutated target sites. The individual role of the amino acid mutations cannot be predicted
correctly without the crystal structure, or at least modeling of the mutations with respect
to available crystal structure of the wild type recombinase, nevertheless it is possible to at
least get an idea of the probable plasticity residues which are players in determining the
substrate specificity of an enzyme.
The other most hypervariable codon was E262. One of the common features in the target
sites used to evolve recombinase variants till now, that is, loxM7, loxK2, loxH and the
loxltr substrates have mutations within residues 5 to 8 in the inverted repeat sites
(Fig.30).
All sequenced recombinases for loxltr and the loxltr2 sub-set displayed an E262Q
mutation and few clones for loxltr1b, loxltr2b and loxltr1 had the glutamate mutated to
Ala or Gln or Arg or His. The Fre recombinases also had Glu at 262 mutated to Gln, or
Ala or Gly (Buchholz and Stewart 2001). This residue was mutated to Gly in one of the
loxM7 recombinases and five Cre mutants recognizing loxK2 sites (Rufer and Sauer
2002; Santoro and Schultz 2002). Systematic replacement of the only Glu at 262 with all
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the remaining 19 amino acids revealed that Tyr, Gly, Ala, Gln, Ser or Trp resulted in
detectable recombination at the loxK2 substrate, whilst retaining 100% recombination
proficiency at the native loxP substrate (Rufer and Sauer 2002). The data from the E262
single mutants show that that this Glu262 is an optimal choice for imposing change in
substrate specificity while allowing undiminished recombination at loxP.
Fig.30. Sequence of loxP and mutant lox variants used as target sites in directed evolution
experiments till now. The bases in violet are mutated with respect to loxP. The first seven bases in the
inverted repeats have been labeled.
6.3. Regions of potential plasticity in the Cre recombinase mutants.
Mapping of mutations in the Tre recombinases and also the loxltr1 and loxltr2
recombinases show a wide distribution of mutations throughout the protein, with a high
density of mutations in the extreme N-terminus and on helices D, J and M, and 4-5 β
hairpin and L-M linker (fig.19). Such mutation maps can be informative about the regions
within the protein which are flexible and can tolerate mutations. In the directed evolution
study of Cre to recognize loxH, the resultant Fre recombinases also showed presence of
hypervariable codons on helices D and J and M. The N-terminus was again very tolerant
to mutations with positions 3 and 7 being very persistent, though numerous mutations
near the N- terminus suggest the flexibility of this region of the protein to mutations
(Buchholz and Stewart 2001).
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Recently pentapeptide insertional mutagenesis of Cre was performed to make a functional
map of the recombinase (Petyuk et al. 2004). Pentapeptide scanning mutagenesis is
different from directed evolution studies yet both systems allow the probing of regions of
flexibility in a protein. The study identified 8 major clusters of active insertions and 6
clusters of inactivating insertions. There were regions of no insertions like helices B, E
and J. The loxltr recombinases however showed persistent mutations between positions
259 and 263 on helix J. The B and E helices in our case also showed either no or single
mutation. The insertions in the above study concentrated mainly to the extreme N-
terminus, and loop between helices J and K. It was found that four non-conserved linker
and loop regions do not tolerate mutations, A-B, E-F, 3-I and M-N. The more structured
and presumably functionally important regions like the helix A, 4-5 β hairpin, which is
evolutionarily flexible and the J-K loop which contact the DNA in the minor groove were
tolerant to mutations. In general the inactivating insertions occurred in regions more
buried and the non-inactivating insertions were in regions which were more solvent
accessible. The evolved Tre and loxltr1 and loxltr2 recombinases showed highly
recurssive mutations at positions 317 and 320 in the L-M region, but the A-B, E-F, 3-I
and M-N regions have either very low or no mutations showing that these regions allow
little to no changes to maintain function and also is in agreement with the data from the
pentapeptide mutagenesis study. The extreme N-terminus (including helix A) for the Tre
recombinases was also very tolerant to mutations. The outcome of mutation distribution
depends on the mutagenesis protocol, but such comparative analysis would give a clearer
vision of regions in the recombinases which might be further explored for their function
in enzyme catalysis and specificity. In general adaptive mutations that affect substrate
specificity are difficult to identify. Preponderance of apparently neutral mutations in
molecular evolution (Kimura 1983) makes it difficult to identify adaptive mutations
through sequence comparison alone. The relationship between structure and function of
proteins are often unclear even when an X-ray crystal structure is available. An important
determinant of substrate specificity is the conformational dynamics of a protein, and
mutations which affect this property can occur anywhere in the protein (James and
Tawfik 2003). However the role of seemingly interesting mutations that get fixed over
the course of evolution can be dissected by using site-directed mutagenesis to create
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single or multiple mutants and characterize the mutations which are synergistic with
respect to catalytic efficiency and specificity.
Based on the sequence information from the loxltr recombinases and other published Cre
variants and mutagenesis studies, it could be worthwhile to focus on the regions like
those in and around helices D, J, M, the 4-5 β hairpin and L-M linker, which have proved
to be flexible to changes, for future directed evolution experiments.
6.4. Modelling of mutations in the selected Tre25 recombinase onto wild type
Cre crystal structure.
The major amino acid mutations in the selected Tre recombinase, Tre25.42 (table4) have
been modeled onto published Cre crystal structure (PDB entry 1Crx) synapsed to lox site
(Guo, Gopaul, and van Duyne 1997). The individual role of the amino acid mutations
cannot be predicted correctly without the crystal structure, however modeling of the
mutations with respect to available crystal structure of the wild type recombinase could
give an idea of how specific mutations might interact with the target site and contribute to
recognition of the loxltr target site.
The recognition of a specific nucleotide sequence by a DNA binding protein is
determined by the numerous atomic interactions between the amino acids of the protein
and nucleotides of the DNA. Systematic analysis of different DNA binding proteins
revealed common interactions between specific amino acids and nucleotides (Pabo and
Sauer 1992; Suzuki and Yagi 1994; Mandel-Gutfreund, Schueler, and Margalit 1995;
Luscombe, Laskowski, and Thornton 2001).
The studies have concluded that though there are some typically favoured interactions
between amino acids and DNA bases, there is no simple code that can describe the
specific recognition of target sites by proteins (Pabo and Sauer 1984; Matthews 1988).
The synergistic effect of hydrogen bonds, van der Waals contact and water mediated
interactions contribute to recognition of specific DNA sequence by a protein.
Inspection of the sequences of the Tre recombinases reveal hypervariable clusters of
mutations that were combined during shuffling of loxltr1 and loxltr2 recombinases for
directing evolution at loxltr. Among these mutations the residues at positions 259, 262
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and 263 all occur in the major groove of DNA. This is important as there are different
hydrogen bond donors and acceptors in the major and minor groove of DNA. This cluster
of mutations interact with the right arm of the asymmetric loxltr site.
        Fig.31.  Sequences of the right arm of loxltr and loxP sequences.
Fig.32. Modelling of amino acid mutations in the Tre25.42 recombinase onto the wild type Cre
crystal structure (1Crx). The first 19 amino acids have not been resolved in the crystal structure and so
the numbers of the residues modeled are actually: Y240 is actually residueY259, Q243 is Q262, R244 is
R263, R225 is R244 and Y226 is Y245. The AT and GC base pairs are shown in green and orange
respectively.
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R259Y mutation:  This residue is in proximity to A7’ and also to preceeding G6’ that has
been mutated to a C in loxltr sequence (Fig.31 and 32). There are several possibilities as
to how this tyrosine might interact with the DNA. On one hand this aromatic residue
might intercalate with the DNA base pair stacks and lead to a kink in the loxltr, which
can change the size and width of the major groove. It is known that aromatic amino acids
and also proline and histidine are able to produce extensive ring stacking interactions
with DNA. When no base is exposed then the side chains of these residues are positioned
with the plane of the ring facing the DNA, which maximizes the contact surface area.
Intercalation with adjacent base stacks lead to kinks in DNA as for integration host factor.
There could also be hydrogen bonding with the DNA in the following ways:
(a). The phenolic group can directly form hydrogen bond with the two proximal hydrogen
bond donors, the N4 of C6’ and also with N6 of A7’. In the modeled structure of
Tre25.42, the N6 of adenine directly faces the planar ring of tyrosine. The mutation from
G6’ to C6’ would also expose the N4 of cytosine towards the edge of the planar ring
(fig.32).
(b). Alternatively a water molecule can be trapped between the DNA and the tyrosine and
provide a bridging interaction for hydrogen bond acceptors for N7 and O6 of guanine, N7
of adenine and O4 of thymine.
E262Q mutation: This residue is close to the unchanged cytosine 5’and the mutated G4’.
Glutamine is known to show a preference for adenine and also guanine. From the
modeled structure the amino group of glutamine would be capable of interacting with the
N7 of G4’ and the carboxy group is oriented towards the sugar moiety in the backbone of
DNA and cannot form hydrogen bonding interactions with the base itself.
G263R mutation: This mutation is predicted to have major impact on the DNA sequence
specificity, as a small non-interactor has been replaced by a bulky and positively charged
arginine. Arginine is known to make the highest number of hydrogen bonds especially
with guanine, and is capable of making bidentate interactions with bases. In a bidentate
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bond, arginine interacts with both N7 and O6 atoms of guanine. Arginine is used most
frequently in such interactions because of the length of the side-chain, the capacity to
interact in different conformations and the ability to produce good hydrogen bonding
geometries.
From the modeled structure (Fig.32), the Arg residue is in close contact with the non-
mutated A8’ and the following cytosine9’ in loxltr (guanine in loxP, Fig.31). Arginine is
close to the guanine in the complementary strand and could make hydrogen bonds with
the N7 and O6 acceptors. The other potential contact is with O4 of thymine in the
complementary strand.
The other recurring mutations that are close to the DNA include the K244R and N245Y
mutations. Both residues are very close to the last two bases in the loxltr right arm, that is
the G12’and G13’.
K244R mutation: In comparison to lysine, arginine provides two hydrogen bond acceptor
sites and could make bidentate interactions with the N7 and O6 of the guanine bases.
N245Y mutation: This mutation lies at the end of the loxltr and is difficult to interpret.
The side-chain of the amino acid is in close proximity to the backbone of DNA, rather
than with any base. An intercalation is suggested by the orientation of the residue, though
it could also involve a hydrogen bond network with the DNA. In general, DNA backbone
interactions are important for stability rather than specificity.
Modelling of the mutations in the Tre25.42 recombinase on the wild type Cre crystal
structure suggests that recognition of the asymmetric site come from the interactions of
the mutations on one side of the binding surface of the protein which interacts with the
right arm, the mutations in the other half are not in proximity to the DNA and their
contribution are relatively difficult to interpret.
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6.5. Relaxed specificity of evolved recombinases.
An important feature of any directed evolution experiment is the specificity of the
generated enzyme variant. It is known that directed evolution tends to produce enzyme
variants with broadened and relaxed substrate specificity (Matsumura and Ellington
2001; Aharoni et al. 2005). As has been discussed in section 4.9, the evolved
recombinases for loxltr1 and loxltr2 analysed, did not display cross-reactivity on the other
target although they did recombine loxP (Fig.16). This could be explained by the fact that
the loxltr1 and loxltr2 were different sites. The Tre recombinases recombining loxltr
which consists of all the mutations of all the subsets, could be expected to recognize and
recombine the six loxltr sub-sets, however while both the Tre15 and Tre25 recombinases
retained their recombinational proficiency at loxP it was interesting to note that Tre 15,
had much higher cross-reactivity on the loxltr subsets, but after 10 more cycles of
screening and selection, the Tre25 recombinase recombined only loxltr2b. This shows
that evolution proceeded to make the recombinase more specific and less promiscuous.
Transitions of a protein from a specialized enzyme into a generalized enzyme and
ultimately a new ‘respecialised’ enzyme is a feature of molecular evolution.
The fact that evolved recombinases retain their native activity at loxP was also shown for
the previously evolved Cre variants for loxH, loxK2 and loxM7. The observation that
substantial changes in the specificity of a protein need not come at the expense of its
native function has also been made in many other directed evolution experiments
(Kumamaru et al. 1998; Wan et al. 1998; Glieder, Farinas, and Arnold 2002; Xia et al.
2002; Aharoni et al. 2005). An evolved protein can acquire increased fitness for a new
function without losing its original function.
Tre recombines loxP to an extent of 50% at an induction when it recombines loxltr to
about 80% (Fig.18). Increasing the evolution cycles would have likely increased further
the activity at loxltr, but the decrease in the activity at loxP is not predictable, as there
was no counterselection of recombinases against recombination at loxP. However, it is an
interesting possibility that the evolved recombinases would lose their activity on loxP
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even without counterselection by continuing with evolution cycles based on positive
selection alone.
In an extensive literature survey on directed evolution of proteins made by Aharoni et al.,
it was shown that in comparison to the wild type counterpart, the original or native
activity of an evolved protein decreased by a factor of around 3.2 on average, whereas the
increase in novel activity was many times more. Taking Fre17 as an example, a
recombinase generated after 20 evolution cycles (Buchholz and Stewart 2001), they have
shown that there was 1.15 fold change in the native activity or recombination at loxP in
comparison to wt Cre, whereas the fold change relative to wt Cre at loxH was 220 times
more. These results were from a comparison based on the choice of evolved
recombinases for integration at either loxP or loxH. Fre 17 was evolved only in presence
of positive selection pressure, whereas, another variant Fre22, which underwent
counterselection, had lost its activity on loxP while retaining 80 fold more activity on
loxH compared to wt Cre.
When Fre17 and Fre22 were compared on the basis of deletion at either loxP or loxH, it
was found that Fre17 recombined loxP with around 46 fold more efficiency than Fre22.
The more specific Fre22 was around two fold more efficient at recombining loxH in
comparison to Fre17. This is in agreement with the fact that counterselection does result
in a respecialised enzyme.
The Tre recombinases were generated using positive selection pressure for recombining
loxltr. To increase the speed at which recombination activity on loxP is lost one could
include counterselection in future evolution experiments to decrease the native activity.
Counterselection may be implemented by use of a pEVO10 like vector with intertwined
loxP and loxltr sites as had been used in the evolution of Fre recombinases (Buchholz and
Stewart 2001). The final loxltr recombinase library can then be enriched for more
specificity at the new target in comparison to the original target.
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6.6. Activity of codon-optimised Tre recombinase (hTre) in mammalian cells.
The transient and stable β-galactosidase based reporter assays in Hela cells revealed that
hTre is active in Hela cells and also in the genomic context when the reporter construct
was integrated into the genome (Fig.24 and 25).
The X-Gal staining of Hela cells and measurement of β-galactosidase activity after co-
transfection with the recombinase and reporter vectors revealed that hTre recombined
loxltr and loxP in mammalian cells. But it was less efficient at recombining loxP than
loxltr, a result consistent with the finding in E.coli. According to the results of transient
β-galactosidase activity in Hela cells, wtCre was around 9 folds more active in
recombining loxP in comparison to hTre, which was around 95 folds more active in
recombining loxltr.
Recombination at loxltr target integrated into the genome was proven by PCR,
measurement of β-galactosidase activity and staining of loxltr stable cell line. As for the
unoptimised Tre, transfection of hTre recombinase vector into the stable cell lines
followed by Southern did not work.
6.7. Evolved recombinase and application in anti-retroviral therapy.
We used HIV-1 LTR based reporter vectors (HIV_T2_LUC and HIV_T2_CAT) to
address the question whether Tre can recombine loxltr in the context of a real LTR and
repress Tat-mediated transactivation of the reporter genes. Such HIV-1 LTR vectors are
routinely used to assay for inhibitors of Tat mediated transcription activation of reporter
constructs.
The transient Tat activation assay in Hela cells showed that recombination at the loxltr
target does decrease the reporter gene activity by almost three fold (Fig.27 and 29). PCR
and sequencing gave proof that the repression in reporter gene activity was due to site-
specific recombination. The luciferase vector with only one loxltr sequence
(HIV_T1_Luc) did not show decrease of luciferase activity in presence of Tre. The result
of transient Tat activation assay using the CAT reporter gave data consistent with the
luciferase assays.
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Further proof that our evolved recombinase can recombine loxltr in the context of a true
LTR integrated into the genome came from the experiments in the CAT Hela stable cell
lines. Tre recombined the CAT Hela stable cell lines, and recombination was detectable
by PCR (Fig.29). The same PCR was used to quantify extent of recombination at the
loxltr target in the genome. The results from the PCR of DNA isolated from CAT Hela 7
cell line after transfection with hTre, were compared to the PCR performed with different
ratios of HIV_CAT and recombined HIVΔCAT vector. The results indicated that hTre
recombined loxltr integrated into the genome to an extent of 10%. If Cre mediated
recombination at loxP target integrated in the genome represents 100% recombination,
then hTre has one-tenth of recombination efficiency at loxltr compared to Cre at loxP.
To obtain a more active recombinase additional evolution cycles would be necessary. The
activity of the evolved hTre recombinase would not be sufficient for efficient removal of
an integrated provirus from the genome, however, the study provides proof of concept
that evolution can be used for engineering Cre for therapeutic site- specific recombination
based anti -retroviral therapy.
6.8. From proof of principle to application- an outlook on directed evolution
for genetic surgery.
 The riches of protein sequence space can provide answers to complex questions.
Laboratory evolution is not quick work, but in the recent years researchers have devised
numerous assays to accelerate this process and maximize the power of evolution that will
permit the generation of novel proteins in a relatively short time-scale.
Zinc-finger proteins represent a great example of how protein engineering and directed
evolution can be used for therapeutic purposes. Zinc fingers can be linked in tandem to
recognize DNA sequences of different lengths with high fidelity. Such modular design
provides a large number of possibilities for specific recognition of DNA. Over the last
few years zinc fingers have been engineered to target longer DNA sequences.  By adding
functional groups to the engineered DNA binding domains silencing or activation of gene
expression can be achieved. Some therapeutic applications of engineered zinc finger
proteins which are being developed include gene correction by homologous
recombination triggered by introducing double stranded breaks using zinc finger
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nucleases for treating monogenic disorders like SCID (Urnov et al. 2005), disruption of
HSV infective cycle (Papworth et al. 2003), activation of VEGF in a human cell line and
animal model (Rebar et al. 2002), inhibition of HIV-1 gene expression (Reynolds et al.
2003).
We have used directed evolution to engineer Cre to recombine an HIV-1 LTR sequence.
Such strategies represents a novel anti-retroviral approach which can be used to target not
only HIV but several other retroviruses associated with an array of different
malignancies, immunodeficiencies and neurological disorders that afflict a large number
of different creatures ranging from fish (WDSV), birds (ALV, RAV, REV) and mammals
(MMTV, MLV, BLV, SIV, FIV, HTLV, HIV).
Retroviruses are characterized by their ability to integrate into the host genome and
persist indefinitely as a provirus flanked on both sides by viral long terminal repeats
which direct the expression of viral genes. Current treatment regimens to combat
retroviral diseases in humans, chiefly ATLL (adult T-cell leukemia/ lymphoma) inflicted
by HTLV-1 and AIDS caused by HIV-1 are chemotherapeutic and based primarily on
enzyme inhibitors. ATLL therapies include nucleoside analogues inhibiting adenosine
deaminase, topoisomerase inhibitors and interferons. Treatment of HIV-1 target three
steps in the replication cycle of the virus (reverse transcriptase, protease and fusion).
Recently clinical efficacy has been demonstrated for new targets like the HIV-1 co-
receptors, gp120, integrase and virion maturation. These developments have encouraged
the pursuit of novel inhibition strategies and non- traditional targets (Chiu et al. 2005;
Hauber et al. 2005). However till date none of these therapies actually remove the
provirus from the host genome which makes eradication of the virus impossible and leads
to gradual development of viral resistance. Excision of the proviral DNA from infected
cells could be achieved by applying the principle of site-specific recombination mediated
through sequences in the flanking LTR repeats of the pro-viral genome. Our study shows
that evolved recombinases like Tre can be generated by laboratory evolution and hence
provides the first example of a strategy targeting the proviral form of a retrovirus.
Realisation of such a recombination mediated genetic surgery to at least pre-clinical
phases can be made possible by taking into consideration three issues: (a) by improving
the evolution approach to generate more active and specific recombinases for the most
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conserved sequence within a retroviral LTR, (b) to prove that evolved recombinases can
be functional in the more physiologically relevant cell types and  (c) to use the best
delivery vehicle to introduce the recombinase,
One of the most important aspect of any directed evolution experiment is the diversity of
the staring mutagenised library. In vitro methods for creating genetic diversity are very
powerful, yet a laborious process when needed to be applied iteratively. Though
evolution in bacteria has advantages like relatively short time scale of individual cycle
and technical simplicity, yet the process requires generation of a huge library of mutant
genes, transfection into cells, screening for improved phenotype, amplification, recovery
and sequencing of the best performers.
A big breakthrough in enhancing diversity was made around two years back when a
group of researchers used somatic hypermutation to evolve new variants of RFP which
showed a shift in fluorescence toward the infrared (Wang et al. 2004). Somatic
hypermutation (SHM) is a process by which B cells specifically mutate immunoglobulins
when activated by antigens. SHM uses activation-induced cytidine deaminase and error
prone DNA repair to introduce point mutations into the rearranged V regions of Ig at a
rate 106 times higher than the rest of the genome. SHM has been used to repair premature
stop codons in non Ig genes. Tsien’s group transfected B cells with monomeric RFP and
generated evolved mRFP mutants with far-red emissions and enhanced photostability
through a process of iterative SHM in a FACs based assay. SHM mediated protein
evolution in B cells does not require the much more laborious in vitro mutagenesis and
screening procedures and allows much more sequence space to be searched. This tool
should not be limited to fluorescent proteins, and should be used for the evolution of new
enzymes. It would be interesting to develop an SHM based evolution protocol for
evolving novel HIV ltr specific recombinases.
Enzymes engineered through laboratory evolution often demonstrate lower catalytic rates
and efficiency in comparison to their wild type counterparts. This can be improved by
implementing selection and counterselection assay schemes. Recently directed evolution
of recombinases have capitalized on counterselection to increase the novel specificity of
enzymes and concomitantly decreasing their native or original specificity (Buchholz and
Stewart 2001). It is thus very important to include negative selection in the evolution
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strategy, and cycle the interesting candidates or the final libraries through such rounds of
counterselection.
Tre was evolved to recognize a loxltr sequence with 50% sequence similarity to loxP. A
comparison of loxltr to sequences within 30 other HIV LTRs was made and it was found
that the loxltr had a sequence similarity ranging from 70 to 90%. The generated loxltr
specific libraries can be used as the starting library to direct evolution for other loxltr like
sequences.
Finally it is very important to be able to deliver the therapeutic proteins to the right
destination. Controlled delivery of Cre recombinase to specific target tissues have been
made by using recombinant viral vectors. E1- deleted first generation adenoviral Cre
vectors have been used to mediate recombination in tissue culture (Anton and Graham
1995); (Kanegae et al. 1996), in mice for gene targeting in the liver (Akagi et al. 1997);
(Chang et al. 1999a), in the brain (Wang, Krushel, and Edelman 1996) in tumors (Sato et
al. 1998), and in prostate (Leow, Wang, and Gao 2005). These studies demonstrated very
efficient in vivo delivery of the Cre and can be further extended to other evolved
recombinases as well.
Recently protein transduction have been developed as an efficient method to deliver
biologically active proteins directly into mammalian cells (Schwarze, Hruska, and
Dowdy 2000). The 11 amino acid basic peptide fragment from HIV-TAT has been used
to deliver β-galactosidase and the enzyme activity was detected in liver, kidney, brain and
spleen of mice after i.p. injection (Schwarze et al. 1999). Since then a wide variety of full
length Tat fusion proteins ranging from 15 to 121 kDa in size and spanning diverse
functional classes have been effectively delivered into cells with biological activity. A
few examples include TAT-p16, TATp27 (Nagahara et al. 1998), TAT-Cre (Peitz et al.
2002); (Joshi, Hashimoto, and Koni 2002), TAT-HIV protease (Vocero-Akbani et al.
1999). Both primary and transformed cell types including peripheral blood lymphocytes,
fibroblasts, keratinocytes, bone marrow stem cells, osteoclasts, T cells have been
transduced with TAT-proteins. The TAT-Cre fusion protein transduced very efficiently in
fibroblasts, murine embryonic stem cells and primary splenocytes. High transduction
would ensure also higher rate of recombination and can be used to increase
recombination efficiency for evolved recombinases like Tre. One important advantage of
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using protein transduction to deliver recombinases in comparison to viral delivery is that
viral vectors are often found to be toxic due to expression of viral genes in the vector
resulting in triggering of host immune response and loss of transduced cells. Also in spite
of the incorporation of tissue-specific promoters in first generation vectors, there is loss
of specificity and not all tissues are well infected. Thus by combining all the existing
tools in hand, it would be possible to engineer solutions to problems in human
therapeutics by using evolved proteins with desired characteristics.
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